

# US Patent & Trademark Office

## Patent Public Search | Text View

---

United States Patent Application Publication

20250257352

Kind Code

A1

Publication Date

August 14, 2025

Inventor(s)

MCNEILL; Matthew et al.

---

### **METHODS FOR NOMINATION OF NUCLEASE ON-/OFF-TARGET EDITING LOCATIONS, DESIGNATED "CTL-seq" (CRISPR Tag Linear-seq)**

---

#### **Abstract**

Described herein are methods for identifying and nominating on- and off-target CRISPR editing sites with improved accuracy and sensitivity.

---

**Inventors:** MCNEILL; Matthew (Iowa City, IA), TURK; Rolf (Iowa City, IA), RETTIG; Garrett (Coralville, IA), BLACK; Ellen (Swisher, IA), SUN; Yongming (San Ramon, CA), SAILOR; Chris (Cedar Rapids, IA), WANG; Yu (North Grafton, MA), GUNDERSON; Keith (Iowa City, IA), KINNEY; Kyle (Iowa City, IA)

**Applicant:** INTEGRATED DNA TECHNOLOGIES, INC. (Coralville, IA)

**Family ID:** 77338877

**Appl. No.:** 19/067623

**Filed:** February 28, 2025

#### **Related U.S. Application Data**

parent US continuation 17382945 20210722 ABANDONED child US 19067623

us-provisional-application US 63055460 20200723

---

#### **Publication Classification**

**Int. Cl.: C12N15/11 (20060101); C12N9/22 (20060101); C12Q1/6853 (20180101)**

**U.S. Cl.:**

**CPC C12N15/111 (20130101); C12N9/22 (20130101); C12Q1/6853 (20130101);  
C12N2310/20 (20170501)**

---

## **Background/Summary**

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 17/382,945, filed on Jul. 22, 2021, which claims priority to U.S. Provisional Patent Application No. 63/055,460, filed on Jul. 23, 2020, which is incorporated by reference herein in its entirety.

### **REFERENCE TO SEQUENCE LISTING**

[0002] This application was filed with a Sequence Listing XML in ST.26 XML format in accordance with 37 C.F.R. § 1.831. The Sequence Listing XML file submitted in the USPTO Patent Center, “013670-9056-US03\_sequence\_listing\_xml\_1 May 2025.xml,” was created on May 1, 2025, contains 273 sequences, has a file size of 248.0 kilobytes (253,952 bytes), and is incorporated by reference in its entirety into the specification.

### **TECHNICAL FIELD**

[0003] Described herein are methods for identifying and nominating on- and off-target CRISPR editing sites with improved accuracy and sensitivity.

### **BACKGROUND**

[0004] CRISPR (clustered regularly interspaced short palindromic repeats) has revolutionized genomics by permitting the simple introduction of changes to the genetic code. CRISPR systems, such as Cas9 and Cas12a proteins, are guided to their target by RNA oligonucleotide sequences bound by the Cas proteins (forming ribonucleoprotein protein; RNP), where the enzyme creates double stranded breaks (DSBs) in DNA sequences. Native cellular machinery repairs DSBs, generally using non-homologous end joining (NHEJ) or homology directed repair (HDR) molecular pathways. DNA repaired through NHEJ, which occurs at on- and off-target locations, often contains indels (insertions/deletions), which can lead to mutations and change the function of encoded genes. Thus, identifying these locations is critical to deconvoluting the impact of on- and off-target editing on biological phenotypes.

[0005] To date, no “gold standard” method exists to identify or nominate off-target editing locations for CRISPR or other nucleases. Many methods have been developed. These methods use a variety of strategies, including the detection of endogenous repair machinery assembled at DSBs (Discover-Seq [1]), the integration of a DNA tag sequence into the host cell genome (GUIDE-Seq; see U.S. Pat. No. 9,822,407), iGUIDE [2, 3]), or by cutting DNA in vitro (BLISS [4], CIRCLE-Seq [5], SiteSeq [6]).

[0006] Cellular or cell based (sometimes referred to as in vivo) and biochemical (sometimes referred to as in vitro) off-target assay nomination systems each have their advantages. Proteins bound to the DNA and epigenetic marks modify the function of nuclease activity, suggesting that cellular or cell based methods may better identify actual editing targets [7]. However, biochemical methods have nominated sites not identified through cellular or cell based methods, suggesting biochemical methods may be more comprehensive [5, 6]. Nevertheless, these current tools tend to have imperfect sensitivity [5, 6] (see FIG. 1).

[0007] What is needed is a method for detecting and nominating on- and off-target CRISPR editing sites with improved accuracy and sensitivity.

## SUMMARY

[0008] One embodiment described herein is a method for identifying and nominating on- and off-target CRISPR edited sites with improved accuracy and sensitivity, the process comprising the steps of: (a) co-delivering a guide sequence RNA (sgRNA) or a two-part CRISPR RNA: trans-activating crRNA (crRNA: tracrRNA) duplex, one or more tag sequences, and an RNA-guided endonuclease to cells; (b) incubating the cells for a period of time sufficient for double strand breaks to occur; (c) isolating genomic DNA from the cells, fragmenting the genomic DNA, and ligating the fragmented genomic DNA to a unique molecular index containing a universal adapter sequence; (d) amplifying the ligated DNA fragments using primers targeting the tag and universal adapter sequences to produce a first set of amplified sequences; (e) amplifying the first set of amplified sequences using universal sequencing primers targeting the tails of Tag-pTOP or Tag-pBOT primers to produce a second set of amplified sequences; (f) sequencing the pooled sequences and obtaining sequencing data; and (g) identifying on-/off-target CRISPR editing loci. In one aspect, the universal sequencing primers target SP1 or SP2 sequence (SEQ ID NO: 7, 8) tails on the Tag-pTOP or Tag-pBOT primers to produce a second set of amplified sequences. In another aspect, the universal sequencing primers target predefined non-homologous sequence (SEQ ID NO: 269-273) tails on the Tag-pTOP or Tag-pBot primers to produce a second set of amplified sequences. In another aspect, the universal sequencing primers target predefined 13-mer tails on the Tag-pTOP or Tag-pBot primers to produce a second set of amplified sequences. In another aspect, step (g) comprises executing on a processor: (i) aligning the sequence data to a reference genome; (ii) identifying on-/off-target CRISPR editing loci; and (iii) outputting the alignment, analysis, and results data as custom-formatted files, tables or graphics. In another aspect, the method further comprises a step following step (e) comprising: (e1) normalizing the second set of amplified sequences to produce concentration normalized libraries, pooling the normalized libraries with other samples to produce pooled libraries; and continuing with steps (f)-(i). In another aspect, step (d) uses a suppression PCR method. In another aspect, the RNA-guided endonuclease comprises an endogenously-expressed Cas enzyme, a Cas expression vector, a Cas protein, or a Cas RNP complex. In another aspect, the RNA-guided endonuclease comprises an endogenously-expressed Cas9 enzyme, a Cas9 expression vector, a Cas9 protein, or a Cas9 RNP complex. In another aspect, the cells comprise human or mouse cells. In another aspect, the period of time is about 24 hours to about 96 hours. In another aspect, multiple tag sequences are co-delivered. In another aspect, the tag sequences comprise double-stranded deoxyribooligonucleotides (dsDNA) comprising 52-base pairs. In another aspect, the tag sequences comprise a 5'-terminal phosphate, and phosphorothioate linkages between the 1.sup.st and 2.sup.nd, 2.sup.nd and 3.sup.rd, 50.sup.th and 51.sup.st, and 51.sup.st and 52.sup.nd nucleotides. In another aspect, the tag sequences comprise a double stranded DNA comprising the complementary top and bottom strand pairs of SEQ ID NO: 1-2 or 7-268.

[0009] Other embodiments described herein are on- and off-target CRISPR editing sites identified or nominated using the methods described herein.

[0010] Another embodiment described herein is a method for designing 52-base pair tag sequences, the method comprising, executing on a processor: (a) randomly generating 13-nucleotide sequences with 40-90% GC content, max homopolymer length A: 2, C: 3, G: 2, T: 2, weighted homopolymer rate <20, self-folding Tm<50° C., and self-dimer Tm<50° C.; (b) removing sequences that perfectly align to a particular genome or that are homopolymers or GG or CC dinucleotide motifs and obtaining a set of 13-mers; (c) selecting a subset of the 13-mer sequences that contain one or less CC or GG dinucleotide motifs; (d) concatenating four of the of 13-mer subset sequences to form random 52-mer sequences; (e) aligning the random 52-mer sequences to a genome; (f) removing the random 52-mer sequences that have similarity to the genome to produce a subset of 52-mer sequences; and (h) outputting the subset of 52-mer sequences and generating the complementary strands to produce double stranded 52-base pair tag sequences. In one aspect, the genome is human

or mouse. In another aspect, the 52-base pair tag sequences are non complementary to the genome. In another aspect, the method further comprises designing primers for the 52-base pair tag sequences. In another aspect, the 52-base pair tag sequences comprise a 5'-terminal phosphate, and phosphorothioate linkages between the 1.sup.st and 2.sup.nd, 2.sup.nd and 3.sup.rd, 50.sup.th and 51.sup.st, and 51.sup.st and 52.sup.nd nucleotides of the 52-base pair tag sequences. In another aspect, the method further comprises synthesizing oligonucleotides comprising the 52-base pair tag sequences, the complement of the 52-base pair tag sequences, or primers for the 52-base pair tag sequences.

[0011] Other embodiments described herein are one or more 52-base pair tag sequences designed using the methods described herein. In one aspect, the 52-base pair tag sequence comprises a double stranded DNA comprising the top and bottom strand pairs of SEQ ID NO: 1-2 or 7-268.

[0012] Another embodiment described herein is a method for designing primers partially complementary to the 52-base pair tag sequences of claim 23 and an adapter primer, the method comprising, executing on a processor: (a) designing tag primers that are partially complementary to the top and bottom strands of tag sequences; and (b) designing an adapter primer that is partially complementary to the top strand of the adapter sequence; wherein: the tag primers comprise a 5'-universal tail sequence; and the adapter primer comprises a sequence complementary to the tails of Tag-pTOP or Tag-pBOT primers. In one aspect, the 5'-universal tail sequence is complementary to an SP1 or SP2 sequence (SEQ ID NO: 7, 8), a locus specific segment, a ribonucleotide (rN) 6-nucleotides from the 3'-end, a 3'-end mismatch, a 3'-end block (3'-C.sub.3 spacer), a predesigned non-homologous sequence (SEQ ID NO: 269-273), or a predesigned 13-mer sequence. In another aspect, the primers partially complementary to top and bottom strands of the tag sequences comprise a tail sequence complementary to the SP1 sequence (SEQ ID NO: 7) and the adapter primer comprises a sequence complementary to the SP2 sequence (SEQ ID NO: 8) tail on the Tag-pTOP or Tag-pBOT primers; or the primers partially complementary to top and bottom strands of the tag sequences comprise a tail sequence complementary to the SP2 sequence (SEQ ID NO: 8) and the adapter primer comprises a sequence complementary to the SP1 sequence (SEQ ID NO: 7) tail on the Tag-pTOP or Tag-pBOT primers. In another aspect, the amplification of a nucleic acid molecule with the primers that are complementary to the top and bottom strands of tag sequences and primers that are complementary to the top strand of the adapter sequence produces a PCR product that comprises a portion of the tag sequence, a sgDNA sequence, and the adapter sequence. In another aspect, the method further comprises synthesizing oligonucleotides comprising the sequences of the forward and reverse tag primers and the adapter primer. In another aspect, the 52-base pair tag sequences and primers partially complementary to the 52-base pair tag sequences are designed and selected using an algorithm predicting whether the primers are likely to be partially complementary and have a propensity to form primer-dimers.

[0013] Other embodiments described herein are one or more primers partially complementary to the 52-base pair tag sequences and one or more adapter primers designed using the methods described herein. In one aspect, the primers comprise the sequences of SEQ ID NO: 3, 4; and the adapter primer, wherein the adapter primer comprises the sequence of SEQ ID NO: 5.

[0014] Another embodiment described herein is the use of one or more double-stranded 52-base pair tag sequences for identifying on- and off-target CRISPR editing sites.

---

## Description

### DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1 shows fraction of reads shared by three biological replicates are shown in white sectors; whereas reads shared by two replicates, or present in a single replicate, are shown in black sectors. Table 1 shows GUIDE-seq [3] based nomination for 4 different gRNAs in triplicate in a

96-well format. gRNA complexes were generated by mixing equimolar amounts of Alt-R crRNA-XT and Alt-R tracrRNA. HEK293 cells stably expressing Cas9 were transfected with 10 UM gRNA and 0.5 UM dsODN GUIDE-seq tag using the Nucleofector™ system (Lonza). After 72 hrs, genomic DNA (gDNA) was isolated. Genomic DNA was fragmented, and adapters were ligated using the Lotus DNA library preparation kit (IDT). Libraries were generated by amplification from the inserted tag to the ligated adapters [3]. Libraries were then sequenced in paired-end fashion on an Illumina® platform.

[0016] FIG. 2 shows that GUIDE-Seq finds more off-target locations than can be validated through rhAmpSeq targeted amplification. Presented results are an aggregate of 331 GUIDE-Seq nominated sites when delivering gRNA sequences (internally named: AR, CTNNB1, EMX1, GRHRP, HPRT38087, HPRT38285, VEGFA) into HEK293 cells stably expressing WT Cas9. GUIDE-seq nominated off-targets assigned >0.1% of the total reference genome aligned reads for each guide were designed and targeted by one rhAmpSeq panel all reference genome aligned. In subsequent experiments, gRNAs were again delivered to the same cells, and editing was assayed with rhAmpSeq. Targets were called “edited” if the treated condition had observed indels  $\geq$  the untreated control sample at  $\geq 1\%$ .

[0017] FIG. 3 illustrates that GUIDE-Seq tag integration rate varies. The graph shows the percentage of Tag integration (normalized to % Editing) for 118 unique Cas9 on/off-target sites that had InDel editing in rhAmpSeq panels targeting GUIDE-Seq nominated on/off-target loci for guide sequences targeting the RAG1, RAG2, and EMX1 genes. Each guide was co-delivered with the 34-base pair GUIDE-Seq, dsODN tag into HEK293 cells stably expressing Cas9 by nucleofection. DNA was extracted 72 hrs later, amplified by rhAmpSeq multiplex PCR, sequenced on an Illumina® MiSeq, and analyzed through a custom pipeline. The normalized tag integration rate is calculated as the percentage of sequenced reads at each target containing the tag sequence divided by the total reads containing an allele divergent from the reference genome (indicating Cas9 editing).

[0018] FIG. 4 shows the design of rhAmpSeq primers against alien sequence tags. A cartoon diagram shows the steps of the design process using the rhAmpSeq design pipeline including design of forward primers against the top (1) and bottom (2) strands, discarding unneeded primers, and selecting tag-targeting primers that have 5'-overlapping, but not 3'-overlapping sequences, so that the top/bottom strand primer dimers would hairpin (3).

[0019] FIG. 5 shows an overview of the rhAmpSeq design pipeline used to construct the overlapping primer designs. In the pipeline, a known sequence is appended onto the 5'-end and 3'-end of each tag sequence, the inputs are quality-controlled and assays (shown in FIG. 4A) are designed against the top and bottom strand of each tag. Primers targeting each tag strand are paired such that at least 4-nucleotides 3' of the RNA nucleotide do not overlap between primers targeting the same tag, and primer pairs are ranked and selected. Hg38 and mm38 acronyms represent versions of the human and mouse genomes, respectively.

[0020] FIG. 6 illustrates hairpin formation if overlapping primers generate PCR amplicons. The diagram shows a representative target sequence and hairpin PCR product of undesired short amplicons from overlapping primer regions with complementary 5' primer tail ends at the 3'- and 5'-end of the PCR product.

[0021] FIG. 7 shows the number of target sites (black bars) with integration of the specified single tag (SEQ ID NO: 9-40) or pools of tags described in Table 5 (SEQ ID NO: 9-40, 45-268). The striped bar (CTLmax) shows the maximum number of target sites that theoretically can be found if a combination of the single tags (SEQ ID NO: 9-40) is used (23 sites out of a maximum of 32 sites). Pool A1 contains all the single tags (SEQ ID NO: 9-40). Pools B1-6 contain 16 different tags each (SEQ ID NO: 45-268). Pool C1 contains all tags tested (SEQ ID NO: 9-40, 45-268). Integration events were determined using an in-house data analysis tool.

[0022] FIG. 8 shows the number of target sites (black bars) with integration of the specified single



|                 |   |         |         |                                    |                 |         |        |
|-----------------|---|---------|---------|------------------------------------|-----------------|---------|--------|
| chr12_51288216  | 1.06%                                     | 0.00%   | 0.00%   | chr12_56010621                     | 0.87%           | 0.00%   | 0.00%  |
| chr13_29717148  | 0.48%                                     | 0.00%   | 0.00%   | chr1_3088065                       | 0.29%           | 0.00%   | 0.00%  |
| chr15_73442915  | 0.19%                                     | 0.00%   | 0.55%   | chr10_118045968                    | 0.19%           | 0.00%   | 0.00%  |
| chr14_102199972 | 0.00%                                     | 0.00%   | 0.68%   | chr18_56334679                     | 0.00%           | 0.00%   | 2.33%  |
| chr21_36426137  | 0.00%                                     | 0.00%   | 2.19%   | chr5_139002763                     | 0.00%           | 0.00%   | 3.83%  |
| chrX_58291642   | 0.00%                                     | 0.00%   | 3.83%   | Location C17orf99_BR1 C17orf99_BR2 |                 |         |        |
| C17orf99_BR3    | chr17_78164110                            | 100.00% | 100.00% | 100.00%                            | chr22_24471716  | 15.00%  | 13.24% |
| 10.86%          | chr10_101156881                           | 6.22%   | 11.07%  | 9.79%                              | chr3_170476431  | 5.86%   | 3.97%  |
| 4.57%           | chr17_17692965                            | 4.94%   | 0.66%   | 8.62%                              | chr15_73400031  | 3.93%   | 4.63%  |
| 5.73%           | chr19_15238775                            | 0.00%   | 0.00%   | 2.56%                              | chr2_18362316   | 0.00%   | 1.59%  |
| chr2_171087784  | 0.00%                                     | 0.54%   | 0.84%   | chr22_19959968                     | 0.00%           | 1.26%   | 0.19%  |
| chr22_32114104  | 0.00%                                     | 0.00%   | 4.06%   | chr4_129034015                     | 0.00%           | 0.00%   | 0.33%  |
| chr5_61219030   | 0.00%                                     | 0.00%   | 0.33%   | chr5_66209615                      | 0.00%           | 0.00%   | 1.86%  |
| chr7_69709389   | 0.00%                                     | 0.12%   | 2.75%   | chr7_158662844                     | 0.00%           | 1.44%   | 5.27%  |
| chrX_9567397    | 0.00%                                     | 0.00%   | 0.23%   | chr19_55657073                     | 0.00%           | 0.66%   | 0.00%  |
| chr22_43788032  | 0.00%                                     | 2.47%   | 0.00%   | Location C16orf90_BR1 C16orf90_BR2 |                 |         |        |
| C16orf90_BR3    | chr16_3494817                             | 100.00% | 100.00% | 100.00%                            | chr2_109189307  | 75.32%  | 4.27%  |
| 52.05%          | chr22_24586001                            | 45.45%  | 0.00%   | 0.00%                              | chr10_104736568 | 0.00%   | 0.00%  |
| 8.22%           | Location ATAD3C_BR1 ATAD3C_BR2 ATAD3C_BR3 |         |         | chr1_1450685                       | 100.00%         | 100.00% |        |
| 100.00%         | chr1_1503588                              | 11.73%  | 10.07%  | 9.27%                              | chr1_1516015    | 2.47%   | 1.86%  |
| 5.14%           | chr19_32167960                            | 26.34%  | 0.93%   | 0.00%                              | chr2_111077960  | 0.00%   | 1.12%  |
| 0.00%           |   |         |         |                                    |                 |         |        |

[0025] Additionally, nominated targets may not be replicable or detectable using orthogonal methods. Using the GUIDE-Seq method, the GUIDE-Seq DNA tag was co-delivered with each of 6 guides (each tag is delivered with one guide RNA) to HEK293 cells constitutively expressing Cas9 using nucleofection. rhAmpSeq multiplex amplicon panels were designed to amplify the nominated targets, and we quantified editing in biological replicates. Of the 331 targets nominated by GUIDE-Seq, only 41 (12%) could be verified with rhAmpSeq (see FIG. 2).

[0026] dsDNA tag sequences co-delivered with the guide RNAs into a stably expressing CRISPR cell line, which are used in the NHEJ repair, are incorporated at varying rates. Here, the GUIDE-Seq dsDNA tag was co-delivered with each of 6 guides into HEK293 cells constitutively expressing Cas9. In another aspect, the dsDNA tag sequences co-delivered with CRISPR RNP, which are used in the NHEJ repair, are incorporated at varying rates. Here, the GUIDE-Seq dsDNA tag was co-delivered with each of 6 guides into HEK293 cells constitutively expressing Cas9. rhAmpSeq panels were developed to amplify nominated targets, and in biological replicates, the rates of tag integration were analyzed using a custom analytical pipeline. These results demonstrate that tags are incorporated at 0-85% of edited genomic copies, varying by target (see FIG. 3).

Without being bound by any theory, it is hypothesized that the rate varies by sequence context.

[0027] Described herein are methods to improve the signal to noise ratio by combining Integrated DNA Technology's rhAmpSeq™ technology, suppression PCR, and novel alien DNA sequence designs to nominate nuclease off-target editing locations within a host genome.

[0028] In this method, Cas9, a sgRNA or a two-part CRISPR RNA: trans-activating crRNA (crRNA: tracrRNA) duplex, and one or more double stranded DNA (dsDNA) tag sequences are delivered to cells. Co-delivering multiple tags permits improved tag integration at off-target sites (see below). The tag sequences have sequence content significantly different (i.e., alien) to the host genome. After nuclease introduced DSBs, NHEJ repair will insert the tag sequence(s) into the target site, forming known primer landing sites. After cells have time to repair the DSBs and possibly further divide (such as after 72 hr), genomic DNA is isolated, fragmented (e.g., Covaris® shearing, enzyme-based shearing, Tn5, etc.), ligated a unique molecular index (UMI)-containing universal adapter sequence to the fragmented DNA, and the un-ligated material is removed. Next, the DNA fragments are amplified by targeting primers to the tag and universal adapter sequences

(Round 1 PCR). Using universal primers, a sample index (PCR2) is added, the amplified material is concentration normalized, pooled with other samples, and the pooled material is sequenced on an Illumina® (or similar) machine. The sequenced reads are aligned to a reference genome, and loci where large numbers of reads map may nominate on/off-target locations.

[0029] Alien sequences were designed by generating >1 M random 13-mer sequences with 40-90% GC content, max homopolymer length A: 2, C: 3, G: 2, T: 2, weighted homopolymer rate <20, self-folding  $T_m < 50^\circ \text{C}$ ., and self-dimer  $T_m < 50^\circ \text{C}$ . From the list of sequences, sequences that aligned perfectly against human (GRCh38.p2; hg38) or mouse (GRCh38.p4; mm38) reference genomes or had troubling motif sequences (homopolymers, most G-G or C-C dinucleotide motifs) were removed, resulting in 479 sequences.

[0030] To design the 52-base pair tag sequences described herein, 49 13-mer oligo sequences were selected that contain  $\leq 1$  C or G dinucleotide, and 10,000 unique combinations of four 13-mer sequences were generated. The length of each concatenated sequence (e.g., pasting four 13-mer sequences in a row using software) is 52-nucleotides. Next, each 52-nucleotide tag sequence was aligned against the human (GRCh38.p2) and mouse (GRCh38.p4) genomes using an internally modified version of bwa, called bwa-psm. Implementation of bwa-psm returns all possible secondary matches up to a defined threshold. A set of tag sequences (SEQ ID NO:1-2) were designed that were intended to work as a group, that had no similarity to the human or mouse genomes (max seed size: 7, seed edit distance: 2, max edit distance: 21, max gap open: 2, max gap extension: 3, mismatch penalty: 1, gap open penalty: 1, gap extension penalty: 1).

[0031] Overlapping rhAmpSeq V1 primers (SEQ ID NO: 3-4) were designed complementary to the top and bottom strands of the tag and 5'-end of the adapter sequence (SEQ ID NO: 6) (FIG. 4). The tag-specific primers (SEQ ID NO: 3-4) contain a 5'-universal tail sequence matching the SP1 and SP2 primer sequences (SEQ ID NO: 7-8), a locus specific segment, a ribonucleotide (rN) 6-nucleotides from the 3'-end, a 3'-end mismatch, and a 3'-end block (3'-C3 spacer). The adapter-specific primer (SEQ ID NO: 5) targets the 5'-end of the 5'-P5 adapter sequence (SEQ ID NO: 6), and the adapter sequence contains unique molecular index (UMI) sequence (Table 2). The primers were designed to target the plus and minus strands of the annealed tag such that, if these primers unexpectedly form a dimer, the formed product will hairpin, removing the oligo from the available reaction templates (e.g., suppression PCR). (FIG. 6A-B). Primer sequences targeting the tags were chosen based on a proprietary design algorithm designed and implemented by IDT (internal copy of the algorithm with a public-facing UI: [www.idtdna.com/site/account?ReturnURL=/site/order/designtool/index/RHAMPSEQ](http://www.idtdna.com/site/account?ReturnURL=/site/order/designtool/index/RHAMPSEQ)), which selects the most optimally performing primer pairs to amplify the intended template sequence. (FIG. 5). Primer sequences were assessed for non-specific binding to all other tag sequences and both human and mouse primary genome assemblies to verify they were unlikely to form off-target amplicons when combined with a universal adapter sequence and the presence of human or mouse genomic DNA.

[0032] The primers were desired to work in pairs where one tag-specific primer (top or bottom strand) pairs with the adapter-specific primer (SEQ ID NO:5). This results in the amplification of a molecule that contains a portion of the tag, gDNA, and the adapter sequence when amplified using suppression PCR methods (FIG. 4).

TABLE-US-00002

| TABLE                | 2                    | Sequences           | Used         | for                 | First               | Proof               | of           | Concept | SEQ |
|----------------------|----------------------|---------------------|--------------|---------------------|---------------------|---------------------|--------------|---------|-----|
| Sequence ID          | Type                 | Name (5'.fwdarw.3') | NO           | Tag                 | 9022179029169042579 | T*C*GTTCGTTC        | SEQ          |         |     |
| 04625907201907281    | CGCTCTAACCGG         | ID                  | CGAATCTACCGC | NO:                 | GCATATCTACGC        | 1                   |              |         |     |
| CGCA*A*T             | Tag                  | 9022179029169042579 | A*T*TGCGGCGT | SEQ                 | 04625907201907281_r |                     |              |         |     |
| AGATATGCGCGG         | ID                   | ev                  | TAGATTGCGCGG | NO:                 | TTAGAGCGGAAC        | 2                   | GAAC         | *G*A    | Tag |
| pFWD.ID_Target1:     | acactctttccc         | SEQ                 | Primers      | 9022179029169042579 | tacacgacgctc        | ID                  |              |         |     |
| 04625907201907281.12 | ttccgatctTCT         | NO:                 | 7.150.1.SP1  | ACCGCGCATATC        | 3                   | TACrGCCGCT/         |              |         |     |
| 3SpC3/               | Tag                  | pFWD.ID_Target2:    | acactctttccc | SEQ                 | Primers             | 9022179029169042579 | tacacgacgctc |         |     |
| ID                   | 04625907201907281.11 | ttccgatctATA        | NO:          | 6.140.-1.SP1        | TGCGCGGTAGAT        | 4                   |              |         |     |



TCGCrCGGTTT/ 3SpC3/ Adapter Adapter Primer gtgactggagtt SEQ Primer cagacgtgtgct  
ID cttccgatctAA NO: TGATACGGCGAC 5 CACCGAGATCTA CArCAAGGC/ 3SpC3/ P5  
Adapter Example Sequence AATGATACGGCG SEQ ACCACCGAGATC ID  
TACACTAGATCG NO: CNNWNNWNNACA 6 CTCTTTCCCTAC ACGACGCTCTTC  
CGATC\*T SP1 Sequencing Primer 1 acactctttccc SEQ tacacgacgctc ID ttccgatct NO: 7  
SP2 Sequencing Primer 2 gtgactggagtt SEQ cagacgtgtgct ID cttccgatct NO: 8 “\*”

indicates a phosphorothioate linkage; “rN” indicates a ribonucleotide, where N is the nucleotide preceded by the “r”; “/3SpC3/” indicates a 3'-C.sub.3 spacer.

[0033] One embodiment described herein is a method for identifying and identifying and nominating on- and off-target CRISPR editing sites with improved accuracy and sensitivity, the process comprising the steps of: (a) co-delivering a guide sequence RNA (sgRNA) or a two-part CRISPR RNA: trans-activating crRNA (crRNA: tracrRNA) duplex and one or more tag sequences to cells; (b) incubating the cells for a period of time; (c) isolating genomic DNA from the cells, fragmenting the genomic DNA, and ligating the fragmented genomic DNA to a unique molecular index containing a universal adapter sequence; (d) amplifying the ligated DNA fragments using primers targeting the tag and universal adapter sequences to produce a first set of amplified sequences; (e) amplifying the first set of amplified sequences using universal sequencing primers targeting the tails of Tag-pTOP or Tag-pBOT primers to produce a second set of amplified sequences; (f) sequencing the pooled sequences and obtaining sequencing data; and (g) identifying on-/off-target CRISPR editing loci. In one embodiment, the universal sequencing primers target SP1 or SP2 sequence (SEQ ID NO: 7, 8) tails on the Tag-pTOP or Tag-pBOT primers to produce a second set of amplified sequences. In another embodiment, the universal sequencing primers target predesigned non-homologous sequence (Table 6; SEQ ID NO: 269-273) tails on the Tag-pTOP or Tag-pBot to produce a second set of amplified sequences. In yet another embodiment, the universal primers target predesigned 13-mer tails on the Tag-pTOP or Tag-pBOT primers to produce a second set of amplified sequences. In one embodiment, step (g) comprises executing on a processor: (i) aligning the sequence data to a reference genome; (ii) identifying on-/off-target CRISPR editing loci; and (iii) outputting the alignment, analysis, and results data as tables or graphics. In another embodiment, the method further comprises a step following step (e) comprising: (e1) normalizing the second set of amplified sequences to produce concentration normalized libraries, pooling the normalized libraries with other samples to produce pooled libraries; and continuing with steps (f)-(i). In one aspect, step (d) uses a suppression PCR method. In another aspect, the cells constitutively express a Cas enzyme, are co-delivered with a Cas expression vector, are co-delivered with a Cas protein, or are co-delivered with a Cas RNP complex. In another aspect, the cells constitutively express a Cas9 enzyme, are co-delivered with a Cas9 expression vector, are co-delivered with a Cas9 protein, or are co-delivered with a Cas9 RNP complex. In another aspect, the cells comprise human or mouse cells. In another aspect, the period of time is about 24 hours to about 96 hours. In another aspect, multiple tag sequences are co-delivered. In another aspect, the tag sequences comprise double-stranded deoxyribooligonucleotides (dsDNA) comprising 52-base pairs. In another aspect, the tag sequences comprise a 5'-terminal phosphate, and phosphorothioate linkages between the 1.sup.st and 2.sup.nd, 2.sup.nd and 3.sup.rd, 50.sup.th and 51.sup.st, and 51.sup.st and 52.sup.nd nucleotides. In another aspect, the tag sequences comprise a double stranded DNA comprising the top and bottom strand pairs of SEQ ID NO: 9-40 or 45-268.

[0034] Another embodiment described herein is on- and off-target CRISPR editing sites identified or nominated using the methods described herein.

[0035] Another embodiment described herein is a method for designing 52-base pair tag sequences, the method comprising, executing on a processor: (a) randomly generating 13-nucleotide sequences with 40-90% GC content, max homopolymer length A: 2, C: 3, G: 2, T: 2, weighted homopolymer rate <20, self-folding Tm<50° C., and self-dimer Tm<50° C.; (b) removing sequences that perfectly

align to a particular genome or that are homopolymers or GG or CC dinucleotide motifs and obtaining a set of 13-mers; (c) selecting a subset of the 13-mer sequences that contain one or less CC or GG dinucleotide motifs; (d) concatenating four of the of 13-mer subset sequences to form random 52-mer sequences; (e) aligning the random 52-mer sequences to a genome; (f) removing the random 52-mer sequences that have similarity to the genome to produce a subset of 52-mer sequences; and (h) outputting the subset of 52-mer sequences and generating the complementary strands to produce double stranded 52-base pair tag sequences. In one aspect, the genome is human or mouse. In one aspect, the 52-base pair tag sequences are not complementary to the genome. In another aspect, the method further comprises designing primers for the 52-base pair tag sequences. In another aspect, the 52-base pair tag sequences comprise a 5'-terminal phosphate, and phosphorothioate linkages between the 1.sup.st and 2.sup.nd, 2.sup.nd and 3.sup.rd, 50.sup.th and 51.sup.st, and 51.sup.st and 52.sup.nd nucleotides of the 52-base pair tag sequences. In another aspect, the method further comprises synthesising oligonucleotides comprising the 52-base pair tag sequences, the complement of the 52-base pair tag sequences, or primers for the 52-base pair tag sequences.

[0036] Another embodiment described herein is one or more 52-base pair tag sequences designed using the methods described herein. In one aspect, the 52-base pair tag sequence comprises a double stranded DNA comprising the complementary top and bottom strand pairs of SEQ ID NO: 9-40 or 45-268.

[0037] Another embodiment described herein is a method for designing primers partially complementary to the 52-base pair tag sequences described herein and an adapter primer, the method comprising, executing on a processor: (a) designing tag primers that are partially complementary to the top and bottom strands of tag sequences; and (b) designing an adapter primer that is partially complementary to the top strand of the adapter sequence; wherein: the tag primers comprise a 5'-universal tail sequence complementary to an SP1 or SP2 sequence (SEQ ID NO: 7, 8), a locus specific segment, a ribonucleotide (rN) 6-nucleotides from the 3'-end, a 3'-end mismatch, and a 3'-end block (3'-C3 spacer); and the adapter primer comprises a sequence complementary to the SP1 or SP2 sequence (SEQ ID NO: 7, 8). In one aspect, the primers partially complementary to top and bottom strands of the tag sequences comprise a sequence complementary to the SP1 sequence and the adapter primer comprises a sequence complementary to the SP2 sequence; or the primers partially complementary to top and bottom strands of the tag sequences comprise a sequence complementary to the SP2 sequence and the adapter primer comprises a sequence complementary to the SP1 sequence. In another aspect, amplification of a nucleic acid molecule with the primers that are complementary to the top and bottom strands of tag sequences and primers that are complementary to the top strand of the adapter sequence produces a PCR product that comprises a portion of the tag sequence, a sgDNA sequence, and the adapter sequence. In another aspect, the method further comprises synthesising oligonucleotides comprising the sequences of the forward and reverse tag primers and the adapter primer.

[0038] In another embodiment described herein, the 52-base pair tag sequences and primers partially complementary to the 52-base pair tag sequences are designed and selected using an algorithm predicting whether the primers are likely to be partially complementary and have a propensity to form primer-dimers.

[0039] Another embodiment described herein is one or more primers partially complementary to the 52-base pair tag sequences and one or more adapter primers designed using the methods described herein. In one aspect, the primers partially complementary to the 52-base pair tag sequence comprise the sequences of SEQ ID NO: 3, 4; and the adapter primer comprises the sequence of SEQ ID NO:5.

[0040] Another embodiment described herein is the use of one or more double-stranded 52-base pair tag sequences for identifying on- and off-target CRISPR editing sites.

[0041] It will be apparent to one of ordinary skill in the relevant art that suitable modifications and

adaptations to the compositions, formulations, methods, processes, and applications described herein can be made without departing from the scope of any embodiments or aspects thereof. The compositions and methods provided are exemplary and are not intended to limit the scope of any of the specified embodiments. All the various embodiments, aspects, and options disclosed herein can be combined in any variations or iterations. The scope of the methods and processes described herein include all actual or potential combinations of embodiments, aspects, options, examples, and preferences herein described. The methods described herein may omit any component or step, substitute any component or step disclosed herein, or include any component or step disclosed elsewhere herein. It should also be understood that embodiments may include and otherwise be implemented by a combination of various hardware, software, and electronic components. For example, various microprocessors and application specific integrated circuits (“ASICs”) can be utilized, as can software of a variety of languages. Also, servers and various computing devices can be used and can include one or more processing units, one or more computer-readable mediums, one or more input/output interfaces, and various connections (e.g., a system bus) connecting the components. Should the meaning of any terms in any of the patents or publications incorporated by reference conflict with the meaning of the terms used in this disclosure, the meanings of the terms or phrases in this disclosure are controlling. Furthermore, the specification discloses and describes merely exemplary embodiments. All patents and publications cited herein are incorporated by reference herein for the specific teachings thereof.

[0042] Various embodiments and aspects of the inventions described herein are summarized by the following clauses:

[0043] Clause 1. A method for identifying and nominating on- and off-target CRISPR edited sites with improved accuracy and sensitivity, the process comprising the steps of: [0044] (a) co-delivering a guide sequence RNA (sgRNA) or a two-part CRISPR RNA: trans-activating crRNA (crRNA: tracrRNA) duplex, one or more tag sequences, and an RNA-guided endonuclease to cells; [0045] (b) incubating the cells for a period of time sufficient for double strand breaks to occur; [0046] (c) isolating genomic DNA from the cells, fragmenting the genomic DNA, and ligating the fragmented genomic DNA to a unique molecular index containing a universal adapter sequence; [0047] (d) amplifying the ligated DNA fragments using primers targeting the tag and universal adapter sequences to produce a first set of amplified sequences; [0048] (e) amplifying the first set of amplified sequences using universal sequencing primers targeting the tails of Tag-pTOP or Tag-pBOT primers to produce a second set of amplified sequences; [0049] (f) sequencing the pooled sequences and obtaining sequencing data; and [0050] (g) identifying on-/off-target CRISPR editing loci.

[0051] Clause 2. The method of clause 1, wherein the universal sequencing primers target SP1 or SP2 sequence (SEQ ID NO: 7, 8) tails on the Tag-pTOP or Tag-pBOT primers to produce a second set of amplified sequences.

[0052] Clause 3. The method of clause 1 or 2, wherein the universal sequencing primers target predesigned non-homologous sequence (SEQ ID NO: 269-273) tails on the Tag-pTOP or Tag-pBot primers to produce a second set of amplified sequences.

[0053] Clause 4. The method of any one of clauses 1-3, wherein the universal sequencing primers target predesigned 13-mer tails on the Tag-pTOP or Tag-pBot primers to produce a second set of amplified sequences.

[0054] Clause 5. The method of any one of clauses 1-4, wherein step (g) comprises executing on a processor:

[0055] Clause 6. aligning the sequence data to a reference genome; [0056] (a) (ii) identifying on-/off-target CRISPR editing loci; and [0057] (b) (iii) outputting the alignment, analysis, and results data as custom-formatted files, tables or graphics.

[0058] Clause 7. The method of any one of clauses 1-5, further comprising a step following step (e) comprising: [0059] (a) (e1) normalizing the second set of amplified sequences to produce

concentration normalized libraries, pooling the normalized libraries with other samples to produce pooled libraries; and continuing with steps (f)-(i).

[0060] Clause 8. The method of any one of clauses 1-6, wherein step (d) uses a suppression PCR method.

[0061] Clause 9. The method of any one of clauses 1-7, wherein the RNA-guided endonuclease comprises an endogenously-expressed Cas enzyme, a Cas expression vector, a Cas protein, or a Cas RNP complex.

[0062] Clause 10. The method of any one of clauses 1-8, wherein the RNA-guided endonuclease comprises an endogenously-expressed Cas9 enzyme, a Cas9 expression vector, a Cas9 protein, or a Cas9 RNP complex.

[0063] Clause 11. The method of any one of clauses 1-9, wherein the cells comprise human or mouse cells.

[0064] Clause 12. The method of any one of clauses 1-10, wherein the period of time is about 24 hours to about 96 hours.

[0065] Clause 13. The method of any one of clauses 1-11, wherein multiple tag sequences are co-delivered.

[0066] Clause 14. The method of any one of clauses 1-12, wherein the tag sequences comprise double-stranded deoxyribooligonucleotides (dsDNA) comprising 52-base pairs.

[0067] Clause 15. The method of any one of clauses 1-13, wherein the tag sequences comprise a 5'-terminal phosphate, and phosphorothioate linkages between the 1.sup.st and 2.sup.nd, 2.sup.nd and 3.sup.rd, 50.sup.th and 51.sup.st, and 51.sup.st and 52.sup.nd nucleotides.

[0068] Clause 16. The method of any one of clauses 1-14, wherein the tag sequences comprise a double stranded DNA comprising the complementary top and bottom strand pairs of SEQ ID NO: 1-2 or 7-268.

[0069] Clause 17. On- and off-target CRISPR editing sites identified or nominated using the method of any one of clauses 1-15.

[0070] Clause 18. A method for designing 52-base pair tag sequences, the method comprising, executing on a processor: [0071] (a) randomly generating 13-nucleotide sequences with 40-90% GC content, max homopolymer length A: 2, C: 3, G: 2, T: 2, weighted homopolymer rate <20, self-folding Tm<50° C., and self-dimer Tm<50° C.; [0072] (b) removing sequences that perfectly align to a particular genome or that are homopolymers or GG or CC dinucleotide motifs and obtaining a set of 13-mers; [0073] (c) selecting a subset of the 13-mer sequences that contain one or less CC or GG dinucleotide motifs; [0074] (d) concatenating four of the of 13-mer subset sequences to form random 52-mer sequences; [0075] (e) aligning the random 52-mer sequences to a genome; [0076] (f) removing the random 52-mer sequences that have similarity to the genome to produce a subset of 52-mer sequences; and [0077] (g) outputting the subset of 52-mer sequences and generating the complementary strands to produce double stranded 52-base pair tag sequences.

[0078] Clause 19. The method of clause 17, wherein the genome is human or mouse.

[0079] Clause 20. The method of clause 17 or 18, wherein the 52-base pair tag sequences are-non complementary to the genome.

[0080] Clause 21. The method of any one of clauses 17-19, further comprising designing primers for the 52-base pair tag sequences.

[0081] Clause 22. The method of any one of clauses 17-20, wherein the 52-base pair tag sequences comprise a 5'-terminal phosphate, and phosphorothioate linkages between the 1.sup.st and 2.sup.nd, 2.sup.nd and 3.sup.rd, 50.sup.th and 51.sup.st, and 51.sup.st and 52.sup.nd nucleotides of the 52-base pair tag sequences.

[0082] Clause 23. The method of any one of clauses 17-21, further comprising synthesizing oligonucleotides comprising the 52-base pair tag sequences, the complement of the 52-base pair tag sequences, or primers for the 52-base pair tag sequences.

[0083] Clause 24. One or more 52-base pair tag sequences designed using the methods of clauses

17-22.

[0084] Clause 25. The 52-base pair tag sequences of clause 23, wherein the 52-base pair tag sequence comprises a double stranded DNA comprising the top and bottom strand pairs of SEQ ID NO: 1-2 or 7-268.

[0085] Clause 26. A method for designing primers partially complementary to the 52-base pair tag sequences of clause 23 and an adapter primer, the method comprising, executing on a processor:

[0086] (a) designing tag primers that are partially complementary to the top and bottom strands of tag sequences; and [0087] (b) designing an adapter primer that is partially complementary to the top strand of the adapter sequence; [0088] (c) wherein: [0089] (d) the tag primers comprise a 5'-universal tail sequence; and [0090] (e) the adapter primer comprises a sequence complementary to the tails of Tag-pTOP or Tag-pBOT primers.

[0091] Clause 27. The method of clause 25, wherein the 5'-universal tail sequence is complementary to an SP1 or SP2 sequence (SEQ ID NO: 7, 8), a locus specific segment, a ribonucleotide (rN) 6-nucleotides from the 3'-end, a 3'-end mismatch, a 3'-end block (3'-C3 spacer), a predesigned non-homologous sequence (SEQ ID NO: 269-273), or a predesigned 13-mer sequence.

[0092] Clause 28. The method of clause 25 or 26, wherein the primers partially complementary to top and bottom strands of the tag sequences comprise a tail sequence complementary to the SP1 sequence (SEQ ID NO: 7) and the adapter primer comprises a sequence complementary to the SP2 sequence (SEQ ID NO: 8) tail on the Tag-pTOP or Tag-pBOT primers; or the primers partially complementary to top and bottom strands of the tag sequences comprise a tail sequence complementary to the SP2 sequence (SEQ ID NO: 8) and the adapter primer comprises a sequence complementary to the SP1 sequence (SEQ ID NO: 7) tail on the Tag-pTOP or Tag-pBOT primers.

[0093] Clause 29. The method of any one of clauses 25-27, wherein the amplification of a nucleic acid molecule with the primers that are complementary to the top and bottom strands of tag sequences and primers that are complementary to the top strand of the adapter sequence produces a PCR product that comprises a portion of the tag sequence, a sgDNA sequence, and the adapter sequence.

[0094] Clause 30. The method of any one of clauses 25-28, further comprising synthesizing oligonucleotides comprising the sequences of the forward and reverse tag primers and the adapter primer.

[0095] Clause 31. The method of any one of clauses 17-21 and 25-29, wherein the 52-base pair tag sequences and primers partially complementary to the 52-base pair tag sequences are designed and selected using an algorithm predicting whether the primers are likely to be partially complementary and have a propensity to form primer-dimers.

[0096] Clause 32. One or more primers partially complementary to the 52-base pair tag sequences and one or more adapter primers designed using the method of clauses 22-25.

[0097] Clause 33. The primers of clause 32, wherein the primers comprise the sequences of SEQ ID NO: 3, 4; and the adapter primer, wherein the adapter primer comprises the sequence of SEQ ID NO: 5.

[0098] Clause 34. Use of one or more double-stranded 52-base pair tag sequences for identifying on- and off-target CRISPR editing sites.

## REFERENCES

[0099] 1. Wienert et al., "Unbiased detection of CRISPR off-targets in vivo using DISCOVER-seq," *Science* 364 (6437): 286-289 (2019). [0100] 2. Nobles et al., "IGUIDE: An improved pipeline for analyzing CRISPR cleavage specificity," *Genome Biol.* 20 (14): 4-9 (2019). [0101] 3. Tsai et al., "GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases," *Nature Biotechnol.* 33 (2): 187-197 (2015). [0102] 4. Yan et al., "BLISS is a versatile and quantitative method for genome-wide profiling of DNA double-strand breaks," *Nature Commun.* 8:15058 (2017). [0103] 5. Tsai et al., "CIRCLE-seq: a highly sensitive in vitro screen for genome-

wide CRISPR-Cas9 nuclease off-targets,” Nature Methods 14 (6): 607-614 (2017). [0104] 6. Cameron et al., “Mapping the genomic landscape of CRISPR-Cas9 cleavage,” Nature Methods 14 (6): 600-606 (2017). [0105] 7. Char and Moosburner, “Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach,” Nature Methods 12 (9): 823-826 (2015). [0106] 8. Rand et al., “Headloop suppression PCR and its application to selective amplification of methylated DNA sequences,” Nucleic Acids Res. 33 (14): e127 (2005).

## EXAMPLES

### Example 1

[0107] This experiment demonstrates the increased efficiency in tag integration when using double-stranded DNA tags with a length of 52-base pairs and varying genetic sequence. The sequences used are shown in Tables 3-5. Double-stranded tags were generated by hybridization of a top strand and a complementary bottom strand (Tables 3-4; SEQ ID NO: 9-40 or 45-268). Sixteen different tag designs were introduced separately into HEK293 cells constitutively expressing Cas9 together with a guideRNA which targets the EMX1 locus. Alternatively, either pools of 16 tags or one pool of 112 tags were introduced into HEK293 cells constitutively expressing Cas9 together with a guideRNA which targets the EMX1 locus. GuideRNAs were electroporated at a concentration of 10  $\mu$ M, whereas the single Tag or pooled Tags were delivered at a final concentration of 0.5  $\mu$ M. Tag integration levels were determined by targeted amplification using rhAmpSeq primers (SEQ ID NO: 3-4), enriching for known on- and off-target sites of the EMX1 guideRNA. The rhAmpSeq pool for EMX1 consists of 32 sites, which represent empirically determined ON and OFF target loci. Amplified products were sequenced on an Illumina® MiSeq, and tag integration levels were determined using custom software. This example shows that tag integration efficiency varies among single tag constructs individually with a range between 6 (CTL021) and 13 (CTL169, CTL079, CTL002) sites out of a maximum of 32 sites, and is therefore sequence dependent (Single Tags, FIG. 7). By taking the mathematical union of the single tag results, a hypothetical number of 23 sites was calculated (CTLmax, FIG. 7). The hypothesis that combining a pool of tags would increase the likelihood of tag integration was tested and was demonstrated (Pooled Tags, Table, FIG. 7). Pool A1 consists of the tags represented in the Single Tags (see Table 5) and demonstrated that 21 tag integration events were detected out of a maximum of 32 sites, which is higher than achieved with any of the single tags. Similarly, Pool B3 demonstrated integration of a tag at 21 sites out of a maximum of 32 sites. Again, variability between pools was shown (Pooled Tags, FIG. 7), indicating optimization of tag designs can potentially maximize tag integration.

TABLE-US-00003 TABLE 3 Sequences Used for Second Proof of Concept

| SEQ ID  | Name    | Sequence (5'.fwdarw.3')     | NO |
|---------|---------|-----------------------------|----|
| CTL085_ | TOP_tag | GTGTCGTACCAATTGACGACACTA    | 9  |
| CTL085_ | BOT_tag | GAATTGGTACGACGACTAGGTGACTAC | 10 |
| CTL169_ | TOP_tag | GAGCGGTTACCAATACGCCGACCTTA  | 11 |
| CTL169_ | BOT_tag | GTATTGGTAACCGCTCGTCCGACTACT | 12 |
| CTL137_ | TOP_tag | GGCTAGGTACCTATTACCGCGTAGTTA | 13 |
| CTL137_ | BOT_tag | TAATAGGTACCTAGCCGAACGACTACT | 14 |
| CTL042_ | TOP_tag | GAATTGGTACCGATCCGCAATACTA   | 15 |
| CTL042_ | BOT_tag | GGATCGGTACCAATTGACGACCTAG   | 16 |
| CTL051_ | TOP_tag | GAATTGGTAACCGCTCGTCCGACCTTA | 17 |

/5Phos/G\*C\*GCGAGTTAAGGTCGGAC SEQ BOT\_tag  
GAGCGGTTACCAATTCGACGCACCGCT ID CGTTA\*C\*C NO: 18 CTL167\_  
/5Phos/T\*T\*CGGCGCTAGGTGCGGC SEQ TOP\_tag  
GTATTGGTAACCGCTCGTCCGTTCGGC ID GCTAG\*G\*T NO: 19 CTL167\_  
/5Phos/A\*C\*CTAGCGCCGAACGGAC SEQ BOT\_tag  
GAGCGGTTACCAATACGCCGCACCTAG ID CGCCG\*A\*A NO: 20 CTL026\_  
/5Phos/T\*A\*CGCGACTAGGTGCGCG SEQ TOP\_tag  
ATTAAGGTACCTATTACCGCGCGACTA ID TGTGC\*G\*C NO: 21 CTL026\_  
/5Phos/G\*C\*GCACATAGTCGCGCGG SEQ BOT\_tag  
TAATAGGTACCTTAATCGCGCACCTAG ID TCGCG\*T\*A NO: 22 CTL068\_  
/5Phos/G\*T\*CGCGCAGTGTAGCGCG SEQ TOP\_tag  
ATTAAGGTACCTATTACCGCGTCGCGA ID CAGTA\*G\*T NO: 23 CTL068\_  
/5Phos/A\*C\*TACTGTGCGGACGCGG SEQ BOT\_tag  
TAATAGGTACCTTAATCGCGCTACACT ID GCGCG\*A\*C NO: 24 CTL138\_  
/5Phos/A\*A\*CCGTCGATCCGCGCGT SEQ TOP\_tag  
AGTATGGTACCGATCCGCAATACTAGC ID GCGAC\*A\*A NO: 25 CTL138\_  
/5Phos/T\*T\*GTCGCGCTAGTATTGC SEQ BOT\_tag  
GGATCGGTACCATACTACGCGCGGATC ID GACGG\*T\*T NO: 26 CTL079\_  
/5Phos/T\*C\*GCTCGATTGGTTACGC SEQ TOP\_tag GCACTACTTATGCGCTCGACTCGTTCCG  
ID GCTAG\*G\*T NO: 27 CTL079\_ /5Phos/A\*C\*CTAGCCGAACGAGTCG SEQ BOT\_tag  
AGCGCATAAGTAGTGCGCGTAACCAAT ID CGAGC\*G\*A NO: 28 CTL063\_  
/5Phos/A\*C\*TGCGAGCGTACTTGTC SEQ TOP\_tag  
GCGCTAGTACCAATTCGACGCAACCGC ID TCGTC\*C\*G NO: 29 CTL063\_  
/5Phos/C\*G\*GACGAGCGGTTGCGTC SEQ BOT\_tag  
GAATTGGTACTAGCGCGACAAGTACGC ID TCGCA\*G\*T NO: 30 CTL168\_  
/5Phos/C\*G\*CATTAGTCGGTGCGGC SEQ TOP\_tag  
GTATTGGTAACCGCTCGTCCGACGCGC ID TACCT\*A\*T NO: 31 CTL168\_  
/5Phos/A\*T\*AGGTAGCGCGTCGGAC SEQ BOT\_tag  
GAGCGGTTACCAATACGCCGCACCGAC ID TAATG\*C\*G NO: 32 CTL021\_  
/5Phos/A\*T\*TGCGGATCGGTGCGTC SEQ TOP\_tag  
GAATTGGTAACCGCTCGTCCGTACGCG ID CACTA\*C\*T NO: 33 CTL021\_  
/5Phos/A\*G\*TAGTGCGCGTACGGAC SEQ BOT\_tag  
GAAGCGGTTACCAATTCGCGCACCGAT ID CCGCA\*A\*T NO: 34 CTL151\_  
/5Phos/T\*C\*GGCGAGTAGTTGCGCG SEQ TOP\_tag  
GTTATGGTACCATAACCGCGCAGTAGT ID ACGCG\*G\*T NO: 35 CTL151\_  
/5Phos/A\*C\*CGCGTACTACTGCGCG SEQ BOT\_tag  
GTTATGGTACCATAACCGCGCAACTAC ID TCGCC\*G\*A NO: 36 CTL002\_  
/5Phos/A\*C\*TAGCGATCGGTACCTA SEQ TOP\_tag  
GCGCCGAAACCTATTACCGCGACCTAG ID CGTTG\*C\*G NO: 37 CTL002\_  
/5Phos/C\*G\*CAACGCTAGGTGCGCG SEQ BOT\_tag  
TAATAGGTTTCGGCGCTAGGTACCGAT ID CGCTA\*G\*T NO: 38 CTL134\_  
/5Phos/T\*A\*GCGCGTCAAGAGCGCG SEQ TOP\_tag  
GTTATGGTTTCGGCGCTAGGTAAACAG ID CGCGT\*C\*G NO: 39 CTL134\_  
/5Phos/C\*G\*ACGCGCTGTAAACCTA SEQ BOT\_tag  
GCGCCGAAACCTAACCAGCGCTCTTGA ID CGCGC\*T\*A NO: 40 GuideSeq\_  
/5Phos/G\*T\*TTAATTGAGTTGTCAT SEQ TOP\_tag ATGTTAATAACGGT\*A\*T ID NO: 41  
GuideSeq\_ /5Phos/A\*T\*ACCGTTATTAACATAT SEQ BOT\_tag GACAACTCAATTAA\*A\*C ID  
NO: 42 EMX1 GAGTCCGAGCAGAAGAAGAA SEQ protospacer ID NO: 43 AR  
GTTGGAGCATCTGAGTCCAG SEQ protospacer ID NO: 44 “/5Phos/” indicates a 5'-phosphate  
moiety; “\*” indicates a phosphorothioate linkage.

## Example 2

[0108] This experiment demonstrates the increased efficiency in tag integration when using double-stranded DNA tags with a length of 52-base pairs and varying genetic sequence. The sequences used are shown in Tables 3-5. Double-stranded tags were generated by hybridization of a top strand and a complementary bottom strand (SEQ ID NO: 9-40 or 45-268). Sixteen different tag designs were introduced separately into HEK293 cells constitutively expressing Cas9 together with a guideRNA which targets the AR locus. Alternatively, either pools of 16 tags or one pool of 112 tags were introduced into HEK293 cells constitutively expressing Cas9 together with a guideRNA which targets the AR locus. GuideRNAs were electroporated at a concentration of 10  $\mu$ M, whereas the single Tag or pooled Tags were delivered at a final concentration of 0.5  $\mu$ M. Tag integration levels were determined by targeted amplification using rhAmpSeq primers (SEQ ID NO: 3-4), enriching for known on- and off-target sites of the AR guideRNA. The rhAmpSeq pool for AR consists of 53 sites which represent empirically determined ON and OFF target loci. Amplified products were sequenced on an Illumina® MiSeq, and tag integration levels were determined using custom software. This example shows that tag integration efficiency varies among single tag constructs individually with a range between 35 (CTL085, CTL134) and 41 sites (CTL002) out of a maximum of 53 sites, and is therefore sequence dependent (Single Tags, Table 5, FIG. 8).

[0109] By taking the mathematical union of the single tag results, a hypothetical number of 47 sites was calculated (CTLmax, FIG. 8). The hypothesis that combining a pool of tags would increase the likelihood of tag integration was tested and was demonstrated (Pooled Tags, Table 5, FIG. 8). Pool B4 (see Table 5) demonstrated that 44 tag integration events were detected out of a maximum of 53 sites, which is higher than achieved with any of the single tags. Again, variability between pools was shown (Pooled Tags, Table 5, FIG. 8), indicating optimization of tag designs can potentially maximize tag integration.

| TABLE-US-00004 | TABLE    | 4 Tag | Sequences Name                       | Sequence (5'.fwdarw.3') | SEQ ID NO     |
|----------------|----------|-------|--------------------------------------|-------------------------|---------------|
| CTL085_TOP_tag | /5Phos/A | *C    | *GAGCGGTAGTCACCTAGTCGTCGTACCAATT     | CGA                     | SEQ ID NO: 45 |
| CTL169_TOP_tag | /5Phos/T | *A    | *GCGCGAGTAGTCGGACGAGCGGTTACCAATACGC  |                         | SEQ ID NO: 46 |
| CTL137_TOP_tag | /5Phos/T | *C    | *GCGACAGTAGTCGTTCCGGCTAGGTACCTATTACC |                         | SEQ ID NO: 47 |
| CTL042_TOP_tag | /5Phos/C | *G    | *CGCTACTAGGTGCGTCGAATTGGTACCGATCCGC  |                         | SEQ ID NO: 48 |
| CTL051_TOP_tag | /5Phos/G | *G    | *TAACGAGCGGTGCGTCGAATTGGTAACCGCTCGT  |                         | SEQ ID NO: 49 |
| CTL167_TOP_tag | /5Phos/T | *T    | *CGGCGCTAGGTGCGGCGTATTGGTAACCGCTCGT  |                         | SEQ ID NO: 50 |
| CTL026_TOP_tag | /5Phos/T | *A    | *CGCGACTAGGTGCGCGATTAAGGTACCTATTACC  |                         | SEQ ID NO: 51 |
| CTL068_TOP_tag | /5Phos/G | *T    | *CGCGCAGTGTAGCGCGATTAAGGTACCTATTACC  |                         | SEQ ID NO: 52 |
| CTL138_TOP_tag | /5Phos/A | *A    | *CCGTCGATCCGCGCGTAGTATGGTACCGATCCGC  |                         | SEQ ID NO: 53 |
| CTL079_TOP_tag | /5Phos/T | *C    | *GCTCGATTGGTTACGCGCACTACTTATGCGCTCG  |                         | SEQ ID NO: 54 |
| CTL063_TOP_tag | /5Phos/A | *C    | *TGCGAGCGTACTTGTGCGGCTAGTACCAATT     | CGA                     | SEQ ID NO: 55 |
| CTL168_TOP_tag | /5Phos/C | *G    | *CATTAGTCGGTGCGGCGTATTGGTAACCGCTCGT  |                         | SEQ ID NO: 56 |
| CTL021_TOP_tag | /5Phos/A | *T    | *TGCGGATCGGTGCGTCGAATTGGTAACCGCTCGT  |                         | SEQ ID NO: 57 |



CCGTACGACCTA\*C\*T CTL151\_TOP\_tag  
/5Phos/T\*C\*GGCGAGTAGTTGCGCGGTTATGGTACCATAACCG SEQ ID NO: 58  
CGCAGTAGTACGCG\*G\*T CTL002\_TOP\_tag  
/5Phos/A\*C\*TAGCGATCGGTACCTAGCGCCGAAACCTATTACC SEQ ID NO: 59  
GCGACCTAGCGTTG\*C\*G CTL134\_TOP\_tag  
/5Phos/T\*A\*GCGCGTCAAGAGCGCGGTTATGGTTTCGGCGCTA SEQ ID NO: 60  
GGTTAACAGCGCGT\*C\*G CTL085\_BOT\_tag  
/5Phos/G\*C\*GCGAGTAGTGTGCGTTCGAATTGGTACGACGACTA SEQ ID NO: 61  
GGTGACTACCGCTC\*G\*T CTL169\_BOT\_tag  
/5Phos/C\*G\*CGGATTAAGGTGCGGCGTATTGGTAACCGCTCGT SEQ ID NO: 62  
CCGACTACTCGCGC\*T\*A CTL137\_BOT\_tag  
/5Phos/A\*C\*GCCGCTAACTACGCGGTAATAGGTACCTAGCCGA SEQ ID NO: 63  
ACGACTACTGTCGC\*G\*A CTL042\_BOT\_tag  
/5Phos/G\*C\*GCGAGTAGTGTATTGCGGATCGGTACCAATTCTGA SEQ ID NO: 64  
CGCACCTAGTAGCG\*C\*G CTL051\_BOT\_tag  
/5Phos/G\*C\*GCGATTAAGGTCGGACGAGCGGTTACCAATTCTGA SEQ ID NO: 65  
CGCACCGCTCGTTA\*C\*C CTL167\_BOT\_tag  
/5Phos/A\*C\*CTAGCGCCGAACGGACGAGCGGTTACCAATACGC SEQ ID NO: 66  
CGCACCTAGCGCCG\*A\*A CTL026\_BOT\_tag  
/5Phos/G\*C\*GCACATAGTCGCGCGGTAATAGGTACCTTAATCG SEQ ID NO: 67  
CGCACCTAGTCGCG\*T\*A CTL068\_BOT\_tag  
/5Phos/A\*C\*TACTGTCGCGACGCGGTAATAGGTACCTTAATCG SEQ ID NO: 68  
CGCTACACTGCGCG\*A\*C CTL138\_BOT\_tag  
/5Phos/T\*T\*GTCGCGCTAGTATTGCGGATCGGTACCATACTAC SEQ ID NO: 69  
GCGCGGATCGACGG\*T\*T CTL079\_BOT\_tag  
/5Phos/A\*C\*CTAGCCGAACGAGTCGAGCGCATAAGTAGTGCGC SEQ ID NO: 70  
GTAACCAATCGAGC\*G\*A CTL063\_BOT\_tag  
/5Phos/C\*G\*GACGAGCGGTTGCGTTCGAATTGGTACTAGCGCGA SEQ ID NO: 71  
CAAGTACGCTCGCA\*G\*T CTL168\_BOT\_tag  
/5Phos/A\*T\*AGGTAGCGCGTCGGACGAGCGGTTACCAATACGC SEQ ID NO: 72  
CGCACCGACTAATG\*C\*G CTL021\_BOT\_tag  
/5Phos/A\*G\*TAGTGCGCGTACGGACGAGCGGTTACCAATTCTGA SEQ ID NO: 73  
CGCACCGATCCGCA\*A\*T CTL151\_BOT\_tag  
/5Phos/A\*C\*CGCGTACTACTGCGCGGTTATGGTACCATAACCG SEQ ID NO: 74  
CGCAACTACTCGCC\*G\*A CTL002\_BOT\_tag  
/5Phos/C\*G\*CAACGCTAGGTGCGGTAATAGGTTTCGGCGCTA SEQ ID NO: 75  
GGTACCGATCGCTA\*G\*T CTL134\_BOT\_tag  
/5Phos/C\*G\*ACGCGCTGTTAACCTAGCGCCGAAACCATAACCG SEQ ID NO: 76  
CGCTCTTGACGCGC\*T\*A CTL161\_TOP\_tag  
/5Phos/T\*A\*CACTGCGCGACACTGCGAGCGTACACCTTAATCG SEQ ID NO: 77  
CGCTAGTTAGCGGC\*G\*T CTL164\_TOP\_tag  
/5Phos/A\*A\*CCGTCGAGTGCACCGCGTACTACTAATGTCGAAC SEQ ID NO: 78  
CGCTACGCGCACTA\*C\*T CTL030\_TOP\_tag  
/5Phos/C\*G\*CGGACTAAGGTGCGCGAGTAGTGTTACGCGCACT SEQ ID NO: 79  
ACTAATCTAGCCGC\*G\*A CTL088\_TOP\_tag  
/5Phos/A\*C\*TAGTGCGACGAACCTACTCGCGCTAACCAATTCTGA SEQ ID NO: 80  
CGCACCGATCGCTA\*G\*T CTL148\_TOP\_tag  
/5Phos/A\*A\*TGTCGAACCGCGCGGAGTAGTGTAACATAACCG SEQ ID NO: 81  
CGCACCTTAGTCCG\*C\*G CTL152\_TOP\_tag  
/5Phos/G\*C\*GTCGAATTGGTACCGCCGACTTATACCAATACGC SEQ ID NO: 82

|   |    |     |     |
|---|----|-----|-----|
| CGCATAGTAGCGC*G*T CTL007_TOP_tag                    |    |     |     |
| /5Phos/A*C*CTAGTAGCGCGGCGTCTGAATTGGTACTAGCGCGA SEQ  | ID | NO: | 83  |
| CAACGCGTAGTATG*G*T CTL141_TOP_tag                   |    |     |     |
| /5Phos/A*C*CGCTCGTTACCGCGCGATTAAAGGTACGCCGCTAA SEQ  | ID | NO: | 84  |
| CTACGGTACGGTCG*G*T CTL064_TOP_tag                   |    |     |     |
| /5Phos/A*C*CGCCGACTTATCGTTCGGCTAGGTACCAATTCGA SEQ   | ID | NO: | 85  |
| CGCACTGCGAGCGT*A*C CTL158_TOP_tag                   |    |     |     |
| /5Phos/A*C*CTTAATCCGCGACTGCGAGCGTACACCTATTACC SEQ   | ID | NO: | 86  |
| GCGCGACGCGCTGT*T*A CTL066_TOP_tag                   |    |     |     |
| /5Phos/A*C*GACGACTAGGTACCGCTCGTTACCTCTTGACGCG SEQ   | ID | NO: | 87  |
| CTAACCAATTCGAC*G*C CTL144_TOP_tag                   |    |     |     |
| /5Phos/A*C*CATACTACGCGGCGGTTCGACATTACCATAACCG SEQ   | ID | NO: | 88  |
| CGCTAGTGCGAGCG*T*A CTL107_TOP_tag                   |    |     |     |
| /5Phos/C*T*TGTACGGCGGTGCGGCGTATTGGTACCAATACGC SEQ   | ID | NO: | 89  |
| CGCTCGTCGCACTA*G*T CTL149_TOP_tag                   |    |     |     |
| /5Phos/G*T*ACGCTCGCAGTACCGCCGACTTATACCTTAATCG SEQ   | ID | NO: | 90  |
| CGCACTAGCGCGAC*A*A CTL008_TOP_tag                   |    |     |     |
| /5Phos/A*C*GACGACTAGGTTATGGTACGGCGTTAGCGCGAGT SEQ   | ID | NO: | 91  |
| AGTACCTTAGTCCG*C*G CTL099_TOP_tag                   |    |     |     |
| /5Phos/A*C*GAGCGGTAGTCATAGGTAGCGCGTTCTTGACGCG SEQ   | ID | NO: | 92  |
| CTAACCGATCGCTA*G*T CTL089_TOP_tag                   |    |     |     |
| /5Phos/A*C*CGATCCGCAATGCGTCTGAATTGGTACCATAACCG SEQ  | ID | NO: | 93  |
| CGCACCGCCGTACA*A*G CTL081_TOP_tag                   |    |     |     |
| /5Phos/A*C*TAGTGCGACGAACACTGTGCGGAACCTATTACC SEQ    | ID | NO: | 94  |
| GCGACCAATCGAGC*G*A CTL075_TOP_tag                   |    |     |     |
| /5Phos/A*C*CGCCGTACAAGTCGCGACAGTAGTAACCGCTCGT SEQ   | ID | NO: | 95  |
| CCGTTCGGCGCTAG*G*T CTL160_TOP_tag                   |    |     |     |
| /5Phos/T*C*GTCGCACTAGTCGCATTAGTCGGTAGTAGTACGC SEQ   | ID | NO: | 96  |
| GGTATAGGTAGCGC*G*T CTL133_TOP_tag                   |    |     |     |
| /5Phos/A*C*CAATTTCGACGCTAGTTAGCGGCGGTACACTACTCG SEQ | ID | NO: | 97  |
| CGCGCACTCGACGG*T*T CTL076_TOP_tag                   |    |     |     |
| /5Phos/C*G*CGGTAATAGGTCGCGGTAATAGGTACGAGCGGTA SEQ   | ID | NO: | 98  |
| GTCACACTACTCGC*G*C CTL024_TOP_tag                   |    |     |     |
| /5Phos/T*C*GGCGAGTAGTTTAGTGCGAGCGTAAGTAGTGCGC SEQ   | ID | NO: | 99  |
| GTAACCAATCGAGC*G*A CTL045_TOP_tag                   |    |     |     |
| /5Phos/G*T*CGCGCAGTGTAGCGCGGTTATGGTACCATAACCG SEQ   | ID | NO: | 100 |
| CGCACTAGTGCGAC*G*A CTL009_TOP_tag                   |    |     |     |
| /5Phos/T*A*TGCGCTCGACTGCGCGATTAAAGGTAATGTCGAAC SEQ  | ID | NO: | 101 |
| CGCAGTAGTACGCG*G*T CTL055_TOP_tag                   |    |     |     |
| /5Phos/A*C*TAGCGCGACAACGACTATGTGCGCACCAATTCGA SEQ   | ID | NO: | 102 |
| CGCTACGCGCACTA*C*T CTL101_TOP_tag                   |    |     |     |
| /5Phos/A*A*CTACTCGCCGACTTGTACGGCGGTACCAATTCGA SEQ   | ID | NO: | 103 |
| CGCAACTAATCCGC*G*C CTL135_TOP_tag                   |    |     |     |
| /5Phos/C*G*CGGATTAAAGGTCTTGTACGGCGGTACCTAGCCGA SEQ  | ID | NO: | 104 |
| ACGTACGCGCACTA*C*T CTL155_TOP_tag                   |    |     |     |
| /5Phos/T*A*GCGCGTCAAGACTTGTACGGCGGTACCGATCCGC SEQ   | ID | NO: | 105 |
| AATGCACTCGACGG*T*T CTL122_TOP_tag                   |    |     |     |
| /5Phos/C*G*CATTAGTCGGTGCGGCGTATTGGTACGACGACTA SEQ   | ID | NO: | 106 |
| GGTACCAATACGCC*G*C CTL080_TOP_tag                   |    |     |     |
| /5Phos/A*C*CTAGTAGCGCGGCGCGGTTATGGTACCGACTAAT SEQ   | ID | NO: | 107 |

|  |    |     |     |
|--|----|-----|-----|
| GCGACTGATCG*G*T CTL126_TOP_tag                     |    |     |     |
| /5Phos/A*C*TACTCGCGCTAACCTAGTCGTCGTAATCTAGCCG SEQ  | ID | NO: | 108 |
| CGATACGCTCGCAC*T*A CTL098_TOP_tag                  |    |     |     |
| /5Phos/A*C*CGCCGCTATACGCGCGATTAAGGTGTACGCTCGC SEQ  | ID | NO: | 109 |
| AGTCGCGGACTAAG*G*T CTL038_TOP_tag                  |    |     |     |
| /5Phos/T*A*CGCGCACTACTAACCGTCGAGTGCGTACGCTCGC SEQ  | ID | NO: | 110 |
| AGTACCGATCGCTA*G*T CTL139_TOP_tag                  |    |     |     |
| /5Phos/G*T*CGCGCAGTGTATAACAGCGCGTCGTTAGTGCGCG SEQ  | ID | NO: | 111 |
| AGAACGACGACTAG*G*T CTL010_TOP_tag                  |    |     |     |
| /5Phos/G*C*GTCGAATTGGTCGCGTAGTATGGTACCGCCGCTA SEQ  | ID | NO: | 112 |
| TACACCAATACGCC*G*C CTL034_TOP_tag                  |    |     |     |
| /5Phos/T*A*CGCGCACTACTTACGCGACTAGGTACCGATCGCT SEQ  | ID | NO: | 113 |
| AGTCGACGCGCTGT*T*A CTL117_TOP_tag                  |    |     |     |
| /5Phos/A*C*GCCGCTAACTATAGTTAGCGGCGTACCAATTCTGA SEQ | ID | NO: | 114 |
| CGCAACTAATCCGC*G*C CTL035_TOP_tag                  |    |     |     |
| /5Phos/C*G*CGGACTAAGGTTAGTTAGCGGCGTTACGCGCACT SEQ  | ID | NO: | 115 |
| ACTACCGATCCGCA*A*T CTL121_TOP_tag                  |    |     |     |
| /5Phos/A*C*GACGACTAGGTACCGCCGACTTATACGCCGCTAA SEQ  | ID | NO: | 116 |
| CTAATAGGTAGCGC*G*T CTL106_TOP_tag                  |    |     |     |
| /5Phos/C*G*GATCGACGGTTGCGCGAGTAGTGTAGTAGTACGC SEQ  | ID | NO: | 117 |
| GGTTACACTGCGCG*A*C CTL059_TOP_tag                  |    |     |     |
| /5Phos/A*T*TGCGGATCGGTACCGCCGACTTATACCGATCCGC SEQ  | ID | NO: | 118 |
| AATTTCGCTCGATTG*G*T CTL157_TOP_tag                 |    |     |     |
| /5Phos/A*C*TGCGAGCGTACACTGCGAGCGTACACCTTAATCG SEQ  | ID | NO: | 119 |
| CGCACCGCTCGTTA*C*C CTL015_TOP_tag                  |    |     |     |
| /5Phos/A*C*TACTGTCGCGATCGTCGCACTAGTTACGCTCGCA SEQ  | ID | NO: | 120 |
| CTAATTGCGGATCG*G*T CTL110_TOP_tag                  |    |     |     |
| /5Phos/G*G*TAACGAGCGGTTCTCGCGCACTAATTAGTGCGCG SEQ  | ID | NO: | 121 |
| AGAACCATACTACG*C*G CTL123_TOP_tag                  |    |     |     |
| /5Phos/A*C*TACTCGCGCTAGCGCGATTAAGGTACCTTAATCG SEQ  | ID | NO: | 122 |
| CGCAACTACTCGCC*G*A CTL014_TOP_tag                  |    |     |     |
| /5Phos/T*A*CGCGCACTACTCTTGTACGGCGGTACCAATTCTGA SEQ | ID | NO: | 123 |
| CGCAACCGTCGAGT*G*C CTL131_TOP_tag                  |    |     |     |
| /5Phos/A*A*CCGTCGATCCGATTGCGGATCGGTACCTTAATCG SEQ  | ID | NO: | 124 |
| CGCACTAGTGCGAC*G*A CTL062_TOP_tag                  |    |     |     |
| /5Phos/A*G*TAGTGCGCGTATACACTGCGCGACACACTACTCG SEQ  | ID | NO: | 125 |
| CGCACCTTAATCCG*C*G CTL044_TOP_tag                  |    |     |     |
| /5Phos/A*C*GCCGTACCATACGCGGTAATAGGTAGTAGTGCGC SEQ  | ID | NO: | 126 |
| GTATTCGCGCTAG*G*T CTL043_TOP_tag                   |    |     |     |
| /5Phos/T*A*GCGCGTCAAGAACCTAGCGTTGCGATAAGTCGGC SEQ  | ID | NO: | 127 |
| GGTAGTAGTACGCG*G*T CTL118_TOP_tag                  |    |     |     |
| /5Phos/C*G*CATTAGTCGGTAATCTAGCCGCGAACCATAACCG SEQ  | ID | NO: | 128 |
| CGCACCGATCGCTA*G*T CTL128_TOP_tag                  |    |     |     |
| /5Phos/T*A*TGGTACGGCGTGCGGCGTATTGGTACGCCGCTAA SEQ  | ID | NO: | 129 |
| CTAATAAGTCGGCG*G*T CTL067_TOP_tag                  |    |     |     |
| /5Phos/G*C*GCGGTTATGGTGCGGCGTATTGGTACGAGCGGTA SEQ  | ID | NO: | 130 |
| GTCAACCGCTCGTC*C*G CTL020_TOP_tag                  |    |     |     |
| /5Phos/C*G*ACTATGTGCGCAACTACTCGCCGAACCATAACCG SEQ  | ID | NO: | 131 |
| CGCTATGCGCTCGA*C*T CTL006_TOP_tag                  |    |     |     |
| /5Phos/T*A*GTTAGCGGCGTACCGCTCGTTACCACCTTAATCG SEQ  | ID | NO: | 132 |

CGCACCTACG\*C\*G CTL017\_TOP\_tag  
/5Phos/C\*G\*CATTAGTCGGTAGTAGTGCGCGTAAACCGCTCGT SEQ ID NO: 133  
CCGTTAGTGCGCGA\*G\*A CTL057\_TOP\_tag  
/5Phos/T\*A\*GCGCGAGTAGTACCGACTAATGCGTCTCGCGCAC SEQ ID NO: 134  
TAAGACTACCGCTC\*G\*T CTL078\_TOP\_tag  
/5Phos/T\*A\*CGCTCGCACTATCGCTCGATTGGTACCGCCGCTA SEQ ID NO: 135  
TACACCATAACCGC\*G\*C CTL031\_TOP\_tag  
/5Phos/A\*C\*CAATCGAGCGAAGTCGAGCGCATAACGCGCTACC SEQ ID NO: 136  
TATACGCCGCTAAC\*T\*A CTL136\_TOP\_tag  
/5Phos/A\*C\*CTTAATCCGCGACTGCGAGCGTACACCGACTAAT SEQ ID NO: 137  
GCGACTACTGTCGC\*G\*A CTL165\_TOP\_tag  
/5Phos/A\*G\*TAGTGCGCGTATCGCTCGATTGGTTCTTGACGCG SEQ ID NO: 138  
CTAGTATAGCGGCG\*G\*T CTL039\_TOP\_tag  
/5Phos/T\*C\*GTCGCACTAGTCGGTACGGTCGGTGCGCACATAG SEQ ID NO: 139  
TCGTATGGTACGGC\*G\*T CTL036\_TOP\_tag  
/5Phos/C\*G\*CGGATTAAGGTAGTCGAGCGCATAACCGCGTACT SEQ ID NO: 140  
ACTACGACGACTAG\*G\*T CTL048\_TOP\_tag  
/5Phos/C\*G\*ACTATGTGCGCTACGCTCGCACTAACACTACTCG SEQ ID NO: 141  
CGCACCTAGCGCCG\*A\*A CTL053\_TOP\_tag  
/5Phos/A\*C\*CGCCGACTTATTCTCGCGCACTAATCGTCGCACT SEQ ID NO: 142  
AGTAACCGTCGATC\*C\*G CTL072\_TOP\_tag  
/5Phos/A\*C\*CTAGCGTTGCGACCGACTAATGCGGGTAACGAGC SEQ ID NO: 143  
GGTTATGGTACGGC\*G\*T CTL096\_TOP\_tag  
/5Phos/C\*G\*CGCTACTAGGTCGCGGTAATAGGTACCTAGCGTT SEQ ID NO: 144  
GCGACCTAGTCGCG\*T\*A CTL150\_TOP\_tag  
/5Phos/C\*G\*TTCGGCTAGGTACTACTCGCGCTACGCATTAGTC SEQ ID NO: 145  
GGTTCGCGACAGTA\*G\*T CTL084\_TOP\_tag  
/5Phos/C\*G\*GACGAGCGGTTGCGCGTAATAGGTACGACGACTA SEQ ID NO: 146  
GGTTAGTTAGCGGC\*G\*T CTL142\_TOP\_tag  
/5Phos/T\*A\*CGCTCGCACTAATTGCGGATCGGTACCGACTAAT SEQ ID NO: 147  
GCGACCGCGTACTA\*C\*T CTL102\_TOP\_tag  
/5Phos/A\*C\*CGACCGTACCGTATGGTACGGCGTTCTTGACGCG SEQ ID NO: 148  
CTAACCTAGCGCCG\*A\*A CTL154\_TOP\_tag  
/5Phos/G\*C\*GCGGATTAGTTAACCGTCGAGTGCACACTACTCG SEQ ID NO: 149  
CGCACTGCGAGCGT\*A\*C CTL112\_TOP\_tag  
/5Phos/A\*C\*CTTAATCCGCGACCGACTAATGCGTACGCGCACT SEQ ID NO: 150  
ACTATAAGTCGGCG\*G\*T CTL145\_TOP\_tag  
/5Phos/A\*C\*CTTAATCCGCGGCGCGGTTATGGTACCGACTAAT SEQ ID NO: 151  
GCGAACCGCTCGTC\*C\*G CTL060\_TOP\_tag  
/5Phos/A\*C\*TGCGAGCGTACCTTGTACGGCGGTACCTAGTAGC SEQ ID NO: 152  
GCGATAAGTCGGCG\*G\*T CTL016\_TOP\_tag  
/5Phos/T\*T\*CGGCGCTAGGTACCTTAGTCCGCGTTTCGGCGCTA SEQ ID NO: 153  
GGTACCTAGCGTTG\*C\*G CTL159\_TOP\_tag  
/5Phos/A\*C\*CTAGTCGCGTACTTGTACGGCGGTACCTAGCCGA SEQ ID NO: 154  
ACGAACCGTCGAGT\*G\*C CTL056\_TOP\_tag  
/5Phos/A\*C\*CATAACCGCGCTACACTGCGCGACACCAATACGC SEQ ID NO: 155  
CGCTATGGTACGGC\*G\*T CTL162\_TOP\_tag  
/5Phos/A\*C\*ACTACTCGCGCTACGCGACTAGGTAATGTCGAAC SEQ ID NO: 156  
CGCACGCCGCTAAC\*T\*A CTL018\_TOP\_tag  
/5Phos/A\*C\*CGACTAATGCGTAACAGCGCGTCGTTAGTGCGCG SEQ ID NO: 157

|  |    |     |     |
|--|----|-----|-----|
| AGAACTTAATCGC*G*C CTL115_TOP_tag                   |    |     |     |
| /5Phos/A*C*GCCGTACCATAACCGACTAATGCGATAAGTCGGC SEQ  | ID | NO: | 158 |
| GGTACCAATACGCC*G*C CTL033_TOP_tag                  |    |     |     |
| /5Phos/G*T*ACGCTCGCAGTCGCGGTAATAGGTTTCGGCGAGTA SEQ | ID | NO: | 159 |
| GTTACCATAACCGC*G*C CTL047_TOP_tag                  |    |     |     |
| /5Phos/C*G*GACGAGCGGTTGCGCGGTTATGGTACTAGTGCGA SEQ  | ID | NO: | 160 |
| CGAGCGCACATAGT*C*G CTL108_TOP_tag                  |    |     |     |
| /5Phos/A*C*TACTCGCGCTAGCGCGATTAAGGTACGCCGCTAA SEQ  | ID | NO: | 161 |
| CTATCGCGGCTAGA*T*T CTL041_TOP_tag                  |    |     |     |
| /5Phos/A*C*CAATTTCGACGCAACTAATCCGCGCACCAATTCGA SEQ | ID | NO: | 162 |
| CGCAGTAGTGCGCG*T*A CTL061_TOP_tag                  |    |     |     |
| /5Phos/A*C*CGCCGCTATACACCTAGCGCCGAAGTACGCTCGC SEQ  | ID | NO: | 163 |
| AGTGTATAGCGGCG*G*T CTL166_TOP_tag                  |    |     |     |
| /5Phos/A*C*ACTACTCGCGCCGGACGAGCGGTTACCAATACGC SEQ  | ID | NO: | 164 |
| CGCTAGCGCGAGTA*G*T CTL012_TOP_tag                  |    |     |     |
| /5Phos/T*C*GTCGCACTAGTACCTTAATCCGCGCGCAACGCTA SEQ  | ID | NO: | 165 |
| GGTACACTACTCGC*G*C CTL052_TOP_tag                  |    |     |     |
| /5Phos/C*G*CGCTACTAGGTACCGACTAATGCGCGCAACGCTA SEQ  | ID | NO: | 166 |
| GGTAATGTCGAACC*G*C CTL153_TOP_tag                  |    |     |     |
| /5Phos/A*C*GAGCGGTAGTCACTACTGTGCGCGACGCAACGCTA SEQ | ID | NO: | 167 |
| GGTTACACTGCGCG*A*C CTL094_TOP_tag                  |    |     |     |
| /5Phos/A*C*CTAGTCGCGTACGCGTAGTATGGTACCGATCGCT SEQ  | ID | NO: | 168 |
| AGTGGTAACGAGCG*G*T CTL095_TOP_tag                  |    |     |     |
| /5Phos/G*C*GGTTCGACATTACCGACTAATGCGTATGCGCTCG SEQ  | ID | NO: | 169 |
| ACTACCTAGCGTTG*C*G CTL105_TOP_tag                  |    |     |     |
| /5Phos/A*C*TGCGAGCGTACTCTCGCGCACTAAACGCCGCTAA SEQ  | ID | NO: | 170 |
| CTACGCGCTACTAG*G*T CTL109_TOP_tag                  |    |     |     |
| /5Phos/C*G*GTACGGTCGGTAATCTAGCCGCGAACCTTAGTCC SEQ  | ID | NO: | 171 |
| GCGACCGCCGTACA*A*G CTL032_TOP_tag                  |    |     |     |
| /5Phos/T*C*GGCGAGTAGTTACGCGCTACCTATTCGCGGCTAG SEQ  | ID | NO: | 172 |
| ATTACGCCGCTAAC*T*A CTL161_BOT_tag                  |    |     |     |
| /5Phos/A*C*GCCGCTAACTAGCGCGATTAAGGTGTACGCTCGC SEQ  | ID | NO: | 173 |
| AGTGTGCGCGCAGTG*T*A CTL164_BOT_tag                 |    |     |     |
| /5Phos/A*G*TAGTGCGCGTAGCGGTTTCGACATTAGTAGTACGC SEQ | ID | NO: | 174 |
| GGTGCACCTCGACGG*T*T CTL030_BOT_tag                 |    |     |     |
| /5Phos/T*C*GCGGCTAGATTAGTAGTGCGCGTAACACTACTCG SEQ  | ID | NO: | 175 |
| CGCACCTTAGTCCG*C*G CTL088_BOT_tag                  |    |     |     |
| /5Phos/A*C*TAGCGATCGGTGCGTTCGAATTGGTTAGCGCGAGT SEQ | ID | NO: | 176 |
| AGTTCGTCGCACTA*G*T CTL148_BOT_tag                  |    |     |     |
| /5Phos/C*G*CGGACTAAGGTGCGCGGTTATGGTACACTACTCG SEQ  | ID | NO: | 177 |
| CGCGCGGTTTCGACA*T*T CTL152_BOT_tag                 |    |     |     |
| /5Phos/A*C*GCGCTACCTATGCGGCGTATTGGTATAAGTCGGC SEQ  | ID | NO: | 178 |
| GGTACCAATTCGAC*G*C CTL007_BOT_tag                  |    |     |     |
| /5Phos/A*C*CATACTACGCGTTGTCGCGCTAGTACCAATTCGA SEQ  | ID | NO: | 179 |
| CGCCGCGCTACTAG*G*T CTL141_BOT_tag                  |    |     |     |
| /5Phos/A*C*CGACCGTACCGTAGTTAGCGGCGTACCTTAATCG SEQ  | ID | NO: | 180 |
| CGCGGTAACGAGCG*G*T CTL064_BOT_tag                  |    |     |     |
| /5Phos/G*T*ACGCTCGCAGTGCGTTCGAATTGGTACCTAGCCGA SEQ | ID | NO: | 181 |
| ACGATAAGTCGGCG*G*T CTL158_BOT_tag                  |    |     |     |
| /5Phos/T*A*ACAGCGCGTCGCGCGGTAATAGGTGTACGCTCGC SEQ  | ID | NO: | 182 |

AGTCGCGATTAAG\*G\*T CTL066\_BOT\_tag  
/5Phos/G\*C\*GTCGAATTGGTTAGCGCGTCAAGAGGTAACGAGC SEQ ID NO: 183  
GGTACCTAGTCGTC\*G\*T CTL144\_BOT\_tag  
/5Phos/T\*A\*CGCTCGCACTAGCGCGGTTATGGTAATGTCGAAC SEQ ID NO: 184  
CGCCGCGTAGTATG\*G\*T CTL107\_BOT\_tag  
/5Phos/A\*C\*TAGTGCGACGAGCGGCGTATTGGTACCAATACGC SEQ ID NO: 185  
CGCACCGCCGTACA\*A\*G CTL149\_BOT\_tag  
/5Phos/T\*T\*GTCGCGCTAGTGCGCGATTAAGGTATAAGTCGGC SEQ ID NO: 186  
GGTACTGCGAGCGT\*A\*C CTL008\_BOT\_tag  
/5Phos/C\*G\*CGGACTAAGGTACTACTCGCGCTAACGCCGTACC SEQ ID NO: 187  
ATAACCTAGTCGTC\*G\*T CTL099\_BOT\_tag  
/5Phos/A\*C\*TAGCGATCGGTTAGCGCGTCAAGAACGCGCTACC SEQ ID NO: 188  
TATGACTACCGCTC\*G\*T CTL089\_BOT\_tag  
/5Phos/C\*T\*TGTACGGCGGTGCGCGGTTATGGTACCAATTCTGA SEQ ID NO: 189  
CGCATTGCGGATCG\*G\*T CTL081\_BOT\_tag  
/5Phos/T\*C\*GCTCGATTGGTCGCGGTAATAGGTTTCGCGACAGT SEQ ID NO: 190  
AGTTCGTCGCACTA\*G\*T CTL075\_BOT\_tag  
/5Phos/A\*C\*CTAGCGCCGAACGGACGAGCGGTTACTACTGTCG SEQ ID NO: 191  
CGACTTGTACGGCG\*G\*T CTL160\_BOT\_tag  
/5Phos/A\*C\*GCGCTACCTATACCGCGTACTACTACCGACTAAT SEQ ID NO: 192  
GCGACTAGTGCGAC\*G\*A CTL133\_BOT\_tag  
/5Phos/A\*A\*CCGTCGAGTGCGCGGAGTAGTGACGCCGCTAA SEQ ID NO: 193  
CTAGCGTCGAATTG\*G\*T CTL076\_BOT\_tag  
/5Phos/G\*C\*GCGAGTAGTGTGACTACCGCTCGTACCTATTACC SEQ ID NO: 194  
GCGACCTATTACCG\*C\*G CTL024\_BOT\_tag  
/5Phos/T\*C\*GCTCGATTGGTTACGCGCACTACTTACGCTCGCA SEQ ID NO: 195  
CTAAACTACTCGCC\*G\*A CTL045\_BOT\_tag  
/5Phos/T\*C\*GTCGCACTAGTGCGCGGTTATGGTACCATAACCG SEQ ID NO: 196  
CGCTACACTGCGCG\*A\*C CTL009\_BOT\_tag  
/5Phos/A\*C\*CGCGTACTACTGCGGTTTCGACATTACCTTAATCG SEQ ID NO: 197  
CGCAGTCGAGCGCA\*T\*A CTL055\_BOT\_tag  
/5Phos/A\*G\*TAGTGCGCGTAGCGTCTGAATTGGTGCGCACATAG SEQ ID NO: 198  
TCGTTGTCGCGCTA\*G\*T CTL101\_BOT\_tag  
/5Phos/G\*C\*GCGGATTAGTTGCGTCGAATTGGTACCGCCGTAC SEQ ID NO: 199  
AAGTCGGCGAGTAG\*T\*T CTL135\_BOT\_tag  
/5Phos/A\*G\*TAGTGCGCGTACGTTTCGGCTAGGTACCGCCGTAC SEQ ID NO: 200  
AAGACCTTAATCCG\*C\*G CTL155\_BOT\_tag  
/5Phos/A\*A\*CCGTCGAGTGCAATTGCGGATCGGTACCGCCGTAC SEQ ID NO: 201  
AAGTCTTGACGCGC\*T\*A CTL122\_BOT\_tag  
/5Phos/G\*C\*GGCGTATTGGTACCTAGTCGTCTGACCAATACGC SEQ ID NO: 202  
CGCACCGACTAATG\*C\*G CTL080\_BOT\_tag  
/5Phos/A\*C\*CGATCGCTAGTCGCATTAGTCGGTACCATAACCG SEQ ID NO: 203  
CGCCGCGCTACTAG\*G\*T CTL126\_BOT\_tag  
/5Phos/T\*A\*GTGCGAGCGTATCGCGGCTAGATTACGACGACTA SEQ ID NO: 204  
GGTTAGCGCGAGTA\*G\*T CTL098\_BOT\_tag  
/5Phos/A\*C\*CTTAGTCCGCGACTGCGAGCGTACACCTTAATCG SEQ ID NO: 205  
CGCGTATAGCGGCG\*G\*T CTL038\_BOT\_tag  
/5Phos/A\*C\*TAGCGATCGGTACTGCGAGCGTACGCACTCGACG SEQ ID NO: 206  
GTTAGTAGTGCGCG\*T\*A CTL139\_BOT\_tag  
/5Phos/A\*C\*CTAGTCGTCGTTCTCGCGCACTAACGACGCGCTG SEQ ID NO: 207

TTATACATCGCGG\*A\*C CTL010\_BOT\_tag  
/5Phos/G\*C\*GGCGTATTGGTGTATAGCGGCGGTACCATACTAC SEQ ID NO: 208  
GCGACCAATTCGAC\*G\*C CTL034\_BOT\_tag  
/5Phos/T\*A\*ACAGCGCGTCGACTAGCGATCGGTACCTAGTCGC SEQ ID NO: 209  
GTAAGTAGTGCGCG\*T\*A CTL117\_BOT\_tag  
/5Phos/G\*C\*GCGGATTAGTTGCGTCGAATTGGTACGCCGCTAA SEQ ID NO: 210  
CTATAGTTAGCGGC\*G\*T CTL035\_BOT\_tag  
/5Phos/A\*T\*TGCGGATCGGTAGTAGTGCGCGTAACGCCGCTAA SEQ ID NO: 211  
CTAACCTTAGTCCG\*C\*G CTL121\_BOT\_tag  
/5Phos/A\*C\*GCGCTACCTATTAGTTAGCGGCGTATAAGTCGGC SEQ ID NO: 212  
GGTACCTAGTCGTC\*G\*T CTL106\_BOT\_tag  
/5Phos/G\*T\*CGCGCAGTGTAACCGCGTACTACTACTACTCG SEQ ID NO: 213  
CGCAACCGTCGATC\*C\*G CTL059\_BOT\_tag  
/5Phos/A\*C\*CAATCGAGCGAATTGCGGATCGGTATAAGTCGGC SEQ ID NO: 214  
GGTACCGATCCGCA\*A\*T CTL157\_BOT\_tag  
/5Phos/G\*G\*TAACGAGCGGTGCGCGATTAAGGTGTACGCTCGC SEQ ID NO: 215  
AGTGTACGCTCGCA\*G\*T CTL015\_BOT\_tag  
/5Phos/A\*C\*CGATCCGCAATTAGTGCGAGCGTAACTAGTGCGA SEQ ID NO: 216  
CGATCGCGACAGTA\*G\*T CTL110\_BOT\_tag  
/5Phos/C\*G\*CGTAGTATGGTTCTCGCGCACTAATTAGTGCGCG SEQ ID NO: 217  
AGAACCGCTCGTTA\*C\*C CTL123\_BOT\_tag  
/5Phos/T\*C\*GGCGAGTAGTTGCGCGATTAAGGTACCTTAATCG SEQ ID NO: 218  
CGCTAGCGCGAGTA\*G\*T CTL014\_BOT\_tag  
/5Phos/G\*C\*ACTCGACGGTTGCGTCGAATTGGTACCGCCGTAC SEQ ID NO: 219  
AAGAGTAGTGCGCG\*T\*A CTL131\_BOT\_tag  
/5Phos/T\*C\*GTCGCACTAGTGCGCGATTAAGGTACCGATCCGC SEQ ID NO: 220  
AATCGGATCGACGG\*T\*T CTL062\_BOT\_tag  
/5Phos/C\*G\*CGGATTAAGGTGCGCGAGTAGTGTGTCGCGCAGT SEQ ID NO: 221  
GTATACGCGCACTA\*C\*T CTL044\_BOT\_tag  
/5Phos/A\*C\*CTAGCGCCGAATACGCGCACTACTACCTATTACC SEQ ID NO: 222  
GCGTATGGTACGGC\*G\*T CTL043\_BOT\_tag  
/5Phos/A\*C\*CGCGTACTACTACCGCCGACTTATCGCAACGCTA SEQ ID NO: 223  
GGTTCTTGACGCGC\*T\*A CTL118\_BOT\_tag  
/5Phos/A\*C\*TAGCGATCGGTGCGCGGTTATGGTTCGCGGCTAG SEQ ID NO: 224  
ATTACCGACTAATG\*C\*G CTL128\_BOT\_tag  
/5Phos/A\*C\*CGCCGACTTATTAGTTAGCGGCGTACCAATACGC SEQ ID NO: 225  
CGCACGCCGTACCA\*T\*A CTL067\_BOT\_tag  
/5Phos/C\*G\*GACGAGCGGTTGACTACCGCTCGTACCAATACGC SEQ ID NO: 226  
CGCACCATAACCGC\*G\*C CTL020\_BOT\_tag  
/5Phos/A\*G\*TCGAGCGCATAGCGCGGTTATGGTTCGGCGAGTA SEQ ID NO: 227  
GTTGCGCACATAGT\*C\*G CTL006\_BOT\_tag  
/5Phos/C\*G\*CGTAGTATGGTGCGCGATTAAGGTGGTAACGAGC SEQ ID NO: 228  
GGTACGCCGCTAAC\*T\*A CTL017\_BOT\_tag  
/5Phos/T\*C\*TCGCGCACTAACGGACGAGCGGTTTACGCGCACT SEQ ID NO: 229  
ACTACCGACTAATG\*C\*G CTL057\_BOT\_tag  
/5Phos/A\*C\*GAGCGGTAGTCTTAGTGCGCGAGACGCATTAGTC SEQ ID NO: 230  
GGTACTACTCGCGC\*T\*A CTL078\_BOT\_tag  
/5Phos/G\*C\*GCGGTTATGGTGTATAGCGGCGGTACCAATCGAG SEQ ID NO: 231  
CGATAGTGCGAGCG\*T\*A CTL031\_BOT\_tag  
/5Phos/T\*A\*GTTAGCGGCGTATAGGTAGCGCGTTATGCGCTCG SEQ ID NO: 232

ACTTCTCGATTG\*G\*T CTL136\_BOT\_tag  
 /5Phos/T\*C\*GCGACAGTAGTCGCATTAGTCGGTGTACGCTCGC SEQ ID NO: 233  
 AGTCGCGGATTAAG\*G\*T CTL165\_BOT\_tag  
 /5Phos/A\*C\*CGCCGCTATACTAGCGCGTCAAGAACCAATCGAG SEQ ID NO: 234  
 CGATACGCGCACTA\*C\*T CTL039\_BOT\_tag  
 /5Phos/A\*C\*GCCGTACCATACGACTATGTGCGCACCGACCGTA SEQ ID NO: 235  
 CCGACTAGTGCGAC\*G\*A CTL036\_BOT\_tag  
 /5Phos/A\*C\*CTAGTCGTCGTAGTAGTACGCGGTTATGCGCTCG SEQ ID NO: 236  
 ACTACCTTAATCCG\*C\*G CTL048\_BOT\_tag  
 /5Phos/T\*T\*CGGCGCTAGGTGCGCGAGTAGTGTTAGTGCGAGC SEQ ID NO: 237  
 GTAGCGCACATAGT\*C\*G CTL053\_BOT\_tag  
 /5Phos/C\*G\*GATCGACGGTTACTAGTGCGACGATTAGTGCGCG SEQ ID NO: 238  
 AGAATAAGTCGGCG\*G\*T CTL072\_BOT\_tag  
 /5Phos/A\*C\*GCCGTACCATAACCGCTCGTTACCCGCATTAGTC SEQ ID NO: 239  
 GGTCGCAACGCTAG\*G\*T CTL096\_BOT\_tag  
 /5Phos/T\*A\*CGCGACTAGGTGCGAACGCTAGGTACCTATTACC SEQ ID NO: 240  
 GCGACCTAGTAGCG\*C\*G CTL150\_BOT\_tag  
 /5Phos/A\*C\*TACTGTGCGGAACCGACTAATGCGTAGCGCGAGT SEQ ID NO: 241  
 AGTACCTAGCCGAA\*C\*G CTL084\_BOT\_tag  
 /5Phos/A\*C\*GCCGCTAACTAACCTAGTCGTCGTACCTATTACC SEQ ID NO: 242  
 GCGAACCGCTCGTC\*C\*G CTL142\_BOT\_tag  
 /5Phos/A\*G\*TAGTACGCGGTGCGCATTAGTCGGTACCGATCCGC SEQ ID NO: 243  
 AATTAGTGCGAGCG\*T\*A CTL102\_BOT\_tag  
 /5Phos/T\*T\*CGGCGCTAGGTTAGCGCGTCAAGAACGCCGTACC SEQ ID NO: 244  
 ATACGGTACGGTCG\*G\*T CTL154\_BOT\_tag  
 /5Phos/G\*T\*ACGCTCGCAGTGCGCGAGTAGTGTCGACTCGACG SEQ ID NO: 245  
 GTTAACTAATCCGC\*G\*C CTL112\_BOT\_tag  
 /5Phos/A\*C\*CGCCGACTTATAGTAGTGCGCGTACGCATTAGTC SEQ ID NO: 246  
 GGTCGCGGATTAAG\*G\*T CTL145\_BOT\_tag  
 /5Phos/C\*G\*GACGAGCGGTTTCGCATTAGTCGGTACCATAACCG SEQ ID NO: 247  
 CGCCGCGGATTAAG\*G\*T CTL060\_BOT\_tag  
 /5Phos/A\*C\*CGCCGACTTATCGCGCTACTAGGTACCGCCGTAC SEQ ID NO: 248  
 AAGGTACGCTCGCA\*G\*T CTL016\_BOT\_tag  
 /5Phos/C\*G\*CAACGCTAGGTACCTAGCGCCGAACGCGGACTAA SEQ ID NO: 249  
 GGTACCTAGCGCCG\*A\*A CTL159\_BOT\_tag  
 /5Phos/G\*C\*ACTCGACGGTTCGTTTCGGCTAGGTACCGCCGTAC SEQ ID NO: 250  
 AAGTACGCGACTAG\*G\*T CTL056\_BOT\_tag  
 /5Phos/A\*C\*GCCGTACCATAGCGGCGTATTGGTGTCGCGCAGT SEQ ID NO: 251  
 GTAGCGCGGTTATG\*G\*T CTL162\_BOT\_tag  
 /5Phos/T\*A\*GTTAGCGGCGTGCGGTTTCGACATTACCTAGTCGC SEQ ID NO: 252  
 GTAGCGCGAGTAGT\*G\*T CTL018\_BOT\_tag  
 /5Phos/G\*C\*GCGATTAAGGTTCTCGCGCACTAACGACGCGCTG SEQ ID NO: 253  
 TTACGCATTAGTCG\*G\*T CTL115\_BOT\_tag  
 /5Phos/G\*C\*GGCGTATTGGTACCGCCGACTTATCGCATTAGTC SEQ ID NO: 254  
 GGTTATGGTACGGC\*G\*T CTL033\_BOT\_tag  
 /5Phos/G\*C\*GCGGTTATGGTAACTACTCGCCGAACCTATTACC SEQ ID NO: 255  
 GCGACTGCGAGCGT\*A\*C CTL047\_BOT\_tag  
 /5Phos/C\*G\*ACTATGTGCGCTCGTCGCACTAGTACCATAACCG SEQ ID NO: 256  
 CGCAACCGCTCGTC\*C\*G CTL108\_BOT\_tag  
 /5Phos/A\*A\*TCTAGCCGCGATAGTTAGCGGCGTACCTTAATCG SEQ ID NO: 257



CGCTAGCCGAGTA\*G\*T CTL041\_BOT\_tag  
 /5Phos/T\*A\*CGCGCACTACTGCGTCGAATTGGTGCGCGGATTA SEQ ID NO: 258  
 GTTGCGTCGAATTG\*G\*T CTL061\_BOT\_tag  
 /5Phos/A\*C\*CGCCGCTATACACTGCGAGCGTACTTCGGCGCTA SEQ ID NO: 259  
 GGTGTATAGCGGCG\*G\*T CTL166\_BOT\_tag  
 /5Phos/A\*C\*TACTCGCGCTAGCGGCGTATTGGTAACCGCTCGT SEQ ID NO: 260  
 CCGGCGCGAGTAGT\*G\*T CTL012\_BOT\_tag  
 /5Phos/G\*C\*GCGAGTAGTGTACCTAGCGTTGCGCGCGGATTAA SEQ ID NO: 261  
 GGTACTAGTGCGAC\*G\*A CTL052\_BOT\_tag  
 /5Phos/G\*C\*GGTTCGACATTACCTAGCGTTGCGCGCATTAGTC SEQ ID NO: 262  
 GGTACCTAGTAGCG\*C\*G CTL153\_BOT\_tag  
 /5Phos/G\*T\*CGCGCAGTGTAACCTAGCGTTGCGTCGCGACAGT SEQ ID NO: 263  
 AGTGACTACCGCTC\*G\*T CTL094\_BOT\_tag  
 /5Phos/A\*C\*CGCTCGTTACCACTAGCGATCGGTACCATACTAC SEQ ID NO: 264  
 GCGTACGCGACTAG\*G\*T CTL095\_BOT\_tag  
 /5Phos/C\*G\*CAACGCTAGGTAGTCGAGCGCATACGCATTAGTC SEQ ID NO: 265  
 GGTAATGTGCAACC\*G\*C CTL105\_BOT\_tag  
 /5Phos/A\*C\*CTAGTAGCGCGTAGTTAGCGGCGTTTAGTGCGCG SEQ ID NO: 266  
 AGAGTACGCT CGCA\*G\*T CTL109\_BOT\_tag  
 /5Phos/C\*T\*TGTACGGCGGTCGCGGACTAAGGTTCGCGGCTAG SEQ ID NO: 267  
 ATTACCGACCGTAC\*C\*G CTL032\_BOT\_tag  
 /5Phos/T\*A\*GTTAGCGGCGTAATCTAGCCGCGAATAGGTAGCG SEQ ID NO: 268  
 CGTAACTACTCGCC\*G\*A “/5Phos/” indicates a 5'-phosphate moiety; “\*” indicates a phosphorothioate linkage.

TABLE-US-00005 TABLE 5 Pools of Tag Sequences Pools Tags Present in Pools Pool A1 Pool B1  
 Pool B2 Pool B3 Pool B4 Pool B5 Pool B6 Pool C1 CTL085 CTL161 CTL089 CTL098 CTL062  
 CTL048 CTL018 Pool A1 CTL169 CTL164 CTL081 CTL038 CTL044 CTL053 CTL115 Pool B1  
 CTL137 CTL030 CTL075 CTL139 CTL043 CTL072 CTL033 Pool B2 CTL042 CTL088 CTL160  
 CTL010 CTL118 CTL096 CTL047 Pool B3 CTL051 CTL148 CTL133 CTL034 CTL128 CTL150  
 CTL108 Pool B4 CTL167 CTL152 CTL076 CTL117 CTL067 CTL084 CTL041 Pool B5 CTL026  
 CTL007 CTL024 CTL035 CTL020 CTL142 CTL061 Pool B6 CTL068 CTL141 CTL045 CTL121  
 CTL006 CTL102 CTL166 CTL138 CTL064 CTL009 CTL106 CTL017 CTL154 CTL012 CTL079  
 CTL158 CTL055 CTL059 CTL057 0TL112 CTL052 CTL063 CTL066 CTL101 CTL157 CTL078  
 0TL145 CTL153 CTL168 CTL144 CTL135 CTL015 CTL031 CTL060 CTL094 CTL021 CTL107  
 CTL155 CTL110 CTL136 CTL016 CTL095 CTL151 CTL149 CTL122 CTL123 CTL165 CTL159  
 CTL105 CTL002 CTL008 CTL080 CTL014 CTL039 CTL056 CTL109 CTL134 CTL099 CTL126  
 CTL131 CTL036 CTL162 CTL032

TABLE-US-00006 TABLE 6 Non-homologous tails Name Sequence (5'.fwdarw.3') SEQ  
 ID NO: H1 ACGCGACTATACGCGCAATATGGT SEQ ID NO: 269 H2  
 CTAGCGATACTACGCGATACGAGAT SEQ ID NO: 270 H3  
 CATAGCGGTATTACGCGAGATTACGA SEQ ID NO: 271 H4  
 CGCGAGTACGTACGATTACCG SEQ ID NO: 272 H5 ACGCGCGACTATACGCGCCTC  
 SEQ ID NO: 273

## Claims

1. A method for identifying and nominating on- and off-target CRISPR edited sites with improved accuracy and sensitivity, the process comprising the steps of: (a) isolating genomic DNA from a cell having one or more tag sequences incorporated into a target site within a genome of the cell; (b) integrating a universal adapter sequence comprising a unique molecular index (UMI) into the

isolated genomic DNA; (c) providing a multiplex PCR reaction mixture comprising: (i) one or more on-target oligonucleotide primers, each having a cleavage region comprising a ribonucleotide (rN) positioned 5' of a blocking group and a complementary region flanking the on-target genome edited locus, wherein the blocking group prevents primer extension and/or inhibits the oligonucleotide primer from serving as a template for DNA synthesis; (ii) one or more adapter-specific oligonucleotide primers, each having a cleavage region comprising a ribonucleotide (rN) positioned 5' of a blocking group and a complementary region flanking the 5' of the universal adapter sequence; and (iii) a cleaving enzyme, wherein the cleaving enzyme is an RNase H2 enzyme; (d) hybridizing the on-target oligonucleotide primer to the on-target genome edited locus to form an on-target double stranded substrate and hybridizing the one or more adapter-specific oligonucleotide primers to the 5' of the universal adapter sequence; (e) cleaving at a point within or adjacent to the cleavage region to remove the blocking group from the one or more on-target oligonucleotide primers and the one or more adapter-specific oligonucleotide primers; and (f) simultaneously amplifying a portion of the isolated genomic DNA comprising the one or more tag sequences and the universal adapter sequence; and (g) sequencing the amplified portion of the isolated genomic DNA, thereby identifying on- and off-target CRISPR edited sites.

**2.** The method of claim 1, wherein the one or more adapter-specific oligonucleotide primers target SP1 or SP2 sequence (SEQ ID NO: 7, 8) tails on a top strand of the one or more on-target oligonucleotide primers or a bottom strand of the one or more on-target oligonucleotide primers.

**3.** The method of claim 1, wherein the one or more adapter-specific oligonucleotide primers target predesigned non-homologous sequence (SEQ ID NO: 269-273) tails on a top strand of the one or more on-target oligonucleotide primers or a bottom strand of the one or more on-target oligonucleotide primers.

**4.** The method of claim 1, wherein the one or more adapter-specific oligonucleotide primers target predesigned 13-mer tails on a top strand of the one or more on-target oligonucleotide primers or a bottom strand of the one or more on-target oligonucleotide primers.

**5.** The method of claim 1, wherein the sequencing of step (g) further comprises executing on a processor: (i) aligning the sequence data to a reference genome; and (ii) outputting the alignment, analysis, and results data as custom-formatted files, tables or graphics.

**6.** (canceled)

**7.** The method of claim 1, wherein step (d) uses a suppression PCR method.

**8.** The method of claim 1, wherein the one or more on-target oligonucleotide primers comprise a first on-target oligonucleotide primer targeting a top strand of the isolated genomic DNA and a second on-target oligonucleotide primer targeting a bottom strand of the isolated genomic DNA.

**9.** The method of claim 1, wherein the one or more adapter-specific oligonucleotide primers comprise a first adapter-specific oligonucleotide primer targeting a top strand of the isolated genomic DNA and a second adapter-specific oligonucleotide primer targeting a bottom strand of the isolated genomic DNA.

**10.** The method of claim 1, wherein the cells comprise human or mouse cells.

**11-12.** (canceled)

**13.** The method of claim 1, wherein the one or more tag sequences comprise double-stranded deoxyribooligonucleotides (dsDNA) comprising 52-base pairs.

**14.** The method of claim 1, wherein the one or more tag sequences comprise a 5'-terminal phosphate, and phosphorothioate linkages between the 1.sup.st and 2.sup.nd, 2.sup.nd and 3.sup.rd, 50.sup.th and 51.sup.st, and 51.sup.st and 52.sup.nd nucleotides.

**15.** The method of claim 1, wherein the one or more tag sequences comprise a double stranded DNA comprising the complementary top and bottom strand pairs of SEQ ID NO: 1-2 or 7-268.

**16.** On- and off-target CRISPR editing sites identified or nominated using the method of claim 1.

**17-33.** (canceled)

**34.** The method of claim 1, wherein the one or more tag sequences alien sequence content

containing no sequence identity to a mouse or human genome.

**35.** The method of claim 1, wherein the cleavage region comprises a ribonucleotide (rN) that is positioned 6-nucleotides from the 3'-end.

---